Most-read are based on citations from 2023 ~ 2025.
Special Articles
-
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020
-
Mee Joo Kang, Kyu-Won Jung, So Hyun Bang, Seo Hyun Choi, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, The Community of Population-Based Regional Cancer Registries*
-
Cancer Res Treat. 2023;55(2):385-399.
-
DOI: https://doi.org/10.4143/crt.2023.447
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.
Conclusion
In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
-
Citations
Citations to this article as recorded by

- Artificial Intelligence in the Training of Radiology Residents: a Multicenter Randomized Controlled Trial
Yanqiu Chen, Zhen Sun, Wenjie Lin, Ziwei Xv, Qichen Su
Journal of Cancer Education.2025; 40(2): 234. CrossRef - Impact of regional medical self-sufficiency on mortality from cancer, stroke and myocardial infarction
Il Yun, Jong Youn Moon
Public Health.2025; 238: 59. CrossRef - Oncoplastic breast reconstruction with single-port laparoscopically harvested omental flap: insights from a ten-year tertiary center experience
K.-H. Yoon, S.-H. Ahn, H.-C. Shin, H. W. Koh, J. K.-H. Park, Y. Myung, J. H. Jeong, C. Y. Heo, E.-K. Kim
Breast Cancer Research and Treatment.2025; 210(2): 355. CrossRef - Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study
So Yeon Kim, Gerard A. Silvestri, Yeon Wook Kim, Roger Y. Kim, Sang-Won Um, Yunjoo Im, Jung Hye Hwang, Seung Ho Choi, Jung Seop Eom, Kang Mo Gu, Yong-Soo Kwon, Shin Yup Lee, Hyun Woo Lee, Dong Won Park, Yeonjeong Heo, Seung Hun Jang, Kwang Yong Choi, Yeol
Journal of Thoracic Oncology.2025; 20(5): 577. CrossRef - Cell free supernatants of Bifidobacterium adolescentis and Bifidobacterium longum suppress the tumor growth in colorectal cancer organoid model
Min Jung Kim, Myoung-Hyun Song, Yo-Sep Ji, Ji Won Park, Young-Kyoung Shin, Soon-Chan Kim, Gihyeon Kim, Beomki Cho, Hansoo Park, Ja-Lok Ku, Seung-Yong Jeong
Scientific Reports.2025;[Epub] CrossRef - Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy
Hyeong Seok Kim, Hochang Chae, Soo Yeun Lim, HyeJeong Jeong, So Jeong Yoon, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Hongbeom Kim
Annals of Surgical Oncology.2025; 32(4): 2799. CrossRef - Trends in Cancer-Screening Rates in Korea: Findings from the National Cancer Screening Survey, 2004-2023
EunKyo Kang, Kui Son Choi, Jae Kwan Jun, Yeol Kim, Hyeon Ji Lee, Chang Kyun Choi, Tae Hee Kim, Sun Hwa Lee, Mina Suh
Cancer Research and Treatment.2025; 57(1): 28. CrossRef - A national estimate of mental disorders and mortality outcomes in cancer survivors
Thi Xuan Mai Tran, Min Sung Chung, Chihwan Cha, Boyoung Park
Cancer.2025;[Epub] CrossRef - The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef - Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study
Hyeong Min Park, Mee Joo Kang, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han
Annals of Surgical Treatment and Research.2025; 108(1): 20. CrossRef - Association of Intensive Endoscopic Burden with Esophageal Cancer Detection: A Nationwide Cohort Study
Yeunji Lee, Eunyoung Lee, Bumhee Park, Gil Ho Lee, Sun Gyo Lim, Sung Jae Shin, Choong-Kyun Noh, Kee Myung Lee
Gut and Liver.2025; 19(1): 59. CrossRef - Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea
Sung Hoon Jeong, Seong Min Chun, Miji Kim, Ye Seol Lee, Jisun Kim, Ja-Ho Leigh, Yoon-Hee Choi
BMC Cancer.2025;[Epub] CrossRef - Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey
Ji Yoon Lee, Ju Won Kim
Medicine International.2025;[Epub] CrossRef - Effectiveness of tailored interventions on quality of life in cancer survivors: A systematic review
Ye Sol Lee, Gi Won Choi, Bohye Kim
Patient Education and Counseling.2025; 134: 108674. CrossRef - Association Between Prostate Cancer Detection Rate and Year of Prostate Biopsy
Young Jun Uhm, Woojin Bang, Jae Hoon Chung, Cheol Young Oh, Hwanik Kim, Jin Seon Cho
Life.2025; 15(2): 260. CrossRef - Impact of Small Area Level Deprivation on Colorectal Cancer Survival: Findings from the Regional Cancer Registry in Korea
Seung Min Hong, Ahreum Kim, Changhoon Kim, Seunghye Jang, Dong Uk Kim, Dong Hoon Baek, Seung Hun Lee, Yu Hyeon Yi, Heeseung Park, Jonghyun Lee, Tae In Kim, Hyun Joo Lee
Cancers.2025; 17(4): 567. CrossRef - Higher suicide risk in type 1 diabetes compared to cancer and the general population in Korea
Seohyun Kim, So Hyun Cho, Rosa Oh, Ji Yoon Kim, You‐Bin Lee, Sang‐Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Gyuri Kim
Journal of Internal Medicine.2025; 297(4): 423. CrossRef - Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study
Sung Hoon Jeong, Seong Min Chun, Hyunji Lee, Miji Kim, Mira Choi, Ja-Ho Leigh
Supportive Care in Cancer.2025;[Epub] CrossRef - Evaluation of the Antioxidant and Anti-Cancer Potential of Microwave-Assisted Opuntia humifusa (Korean Cheonnyencho) Aqueous Extract
Poojitha Yanamala, Jeong-Yun Youn, Prakash Thangavel, Ju-Young Moon, Young-Chul Lee
Current Issues in Molecular Biology.2025; 47(2): 88. CrossRef - Precision Forecasting in Colorectal Oncology: Predicting Six-Month Survival to Optimize Clinical Decisions
Jaehyuk Lee, Youngchae Cho, Yeunwoong Kyung, Eunchan Kim
Electronics.2025; 14(5): 880. CrossRef - Association between Antibiotic Use and Subsequent Risk of Breast Cancer: A Nationwide Retrospective Cohort Study in South Korea
Jaeyi Hong, Sun Jae Park, Young Jun Park, Seogsong Jeong, Seulggie Choi, Jooyoung Chang, Hye Jun Kim, Jihun Song, Ahryoung Ko, Su Gyeong Kim, Minjung Han, Yoosun Cho, Ji Soo Kim, Yun Hwan Oh, Joung Sik Son, Sang Min Park
Cancer Prevention Research.2025; 18(3): 125. CrossRef - Association between fragmented care and incident mood disorder in elderly patients with colorectal cancer: a retrospective cohort study in South Korea
Woo-Ri Lee, Kyu-Tae Han, Woorim Kim
BMC Psychiatry.2025;[Epub] CrossRef - Biennial Mammography Performance in the Korean National Cancer Screening Program From 2009 to 2020
Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Horim A. Hwang, Seung Eun Jung, Hooyeon Lee
Korean Journal of Radiology.2025; 26(4): 313. CrossRef - Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019–2020
Horim A. Hwang, Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Seung Eun Jung, Hooyeon Lee
European Radiology.2025;[Epub] CrossRef - Effects of Pancreatitis and Type 2 Diabetes Mellitus on the Development of Pancreatic Cancer: A Nationwide Nested Case-Control Study
Young-eun Kim, Min Heui Yu, Chung Mo Nam, Eun Seok Kang
Diabetes & Metabolism Journal.2025; 49(2): 252. CrossRef - Novel genetic loci and functional properties of immune-related genes for colorectal cancer survival in Korea
Dabin Yun, Jung-Ho Yang, Soyoun Yang, Jin-ah Sim, Minjung Kim, Ji Won Park, Seung Yong Jeong, Aesun Shin, Sun-Seog Kweon, Nan Song
BMC Cancer.2025;[Epub] CrossRef - Intakes of saturated and unsaturated fat and circulating levels of inflammatory markers among breast cancer survivors
Jiwoo Kim, Hyun Jeong Cho, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Jun Won Min, Yoo Seok Kim, Jung Eun Lee
Scientific Reports.2025;[Epub] CrossRef - Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)
Jieun Lee, Dae-Won Lee, Min Hwan Kim, Jee Hung Kim, Ju Won Kim, Jae-Ho Byun, Kyoung Eun Lee, Myoung Joo Kang, Su-Jin Koh, Soojung Hong, Hye Sung Won, Han Jo Kim, In Hae Park, Seong Hoon Shin, Sun Kyung Baek, Seul-Gi Kim, Sung Ae Koh, Joo Young Jung, Ji-Ye
The Breast.2025; 82: 104500. CrossRef - Analysis of outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: a retrospective nationwide cohort study
Tae-Hwan Kim, Eunyoung Lee, Hyun Woo Lee, Mi Sun Ahn, Yong Won Choi, Minsuk Kwon, Seok Yun Kang, Bumhee Park, Jin-Hyuk Choi
The Oncologist.2025;[Epub] CrossRef - Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer
Ji-Won Kim, Dong Soo Kyung, Won Yeong Ko, Hwang-Phill Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
Gastric Cancer.2025;[Epub] CrossRef - Short-term PM2.5 exposure among 3-year cancer survivors with incident cardiovascular disease before and during the COVID-19 pandemic period
Hyun-Young Shin, Hyeokjong Lee, Jihun Song, Sun Jae Park, Jaewon Kim, Sangwoo Park, Hye Jun Kim, Jina Chung, Kyae Hyung Kim, Sang Min Park
Atmospheric Pollution Research.2025; 16(9): 102574. CrossRef - Assessment of Lung Cancer Risks Related to Family History in Never-Smokers: A Cohort Study
Yun-Gyoo Lee, Dayeon Seo, Hyun-Il Gil, Hyunjoo Lee, Young Hwan Kim, Heerim Nam, Soo-Youn Ham, Du-Young Kang
Clinical Lung Cancer.2025;[Epub] CrossRef - CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma
Joon Young Hur, Kyueng-Whan Min, Yung-Kyun Noh, Young-Woong Won, Yoomi Yeo, Dong-Hoon Kim, Byoung Kwan Son, Mi Jung Kwon, Jung Soo Pyo
Current Medicinal Chemistry.2025; 32(12): 2409. CrossRef - Identification of MMP14 and MKLN1 as colorectal cancer susceptibility genes and drug-repositioning candidates from a genome-wide association study
Dabin Yun, Jung-Ho Yang, Jin-ah Sim, Minjung Kim, Ji Won Park, Seung Yong Jeong, Aesun Shin, Sun-Seog Kweon, Nan Song
Journal of Translational Medicine.2025;[Epub] CrossRef - Risk of hepatocellular carcinoma according to body mass index and waist circumference in nonalcoholic fatty liver disease
Han Na Jung, Ji Hye Heo, Eun Roh, Bum Jun Kim, Minwoo Lee, Jwa-Kyung Kim, Joo-Hee Kim, Boram Han, Kyung-Do Han, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef - Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma
You-Na Sung
American Journal of Cancer Research.2025; 15(3): 1248. CrossRef - A nomogram predicting lymph node metastasis in T1b gastric cancer patients: Korean gastric cancer association-led nationwide survey data
Ji Won Seo, Seung-Taek Lim, Ki Bum Park, Kyong-Hwa Jun, Hyung Min Chin
Asian Journal of Surgery.2025;[Epub] CrossRef - Application of Machine Learning Algorithms for Risk Stratification and Efficacy Evaluation in Cervical Cancer Screening among the ASCUS/LSIL Population: Evidence from the Korean HPV Cohort Study
Heekyoung Song, Hong Yeon Lee, Shin Ah Oh, Jaehyun Seong, Soo Young Hur, Youn Jin Choi
Cancer Research and Treatment.2025; 57(2): 547. CrossRef - Evaluating prostate cancer diagnostic methods: The role and relevance of digital rectal examination in modern era
Younsoo Chung, Sung Kyu Hong
Investigative and Clinical Urology.2025; 66(3): 181. CrossRef - The prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index for survival in patients with colorectal cancer
Xianya Zhu, Qiuping Xu, Yi Zhou, Chunrong Zhu, Lili Zeng
Open Medicine.2025;[Epub] CrossRef - Cryptogenic embolic stroke and cancer
Joaquin Carneado-Ruiz
Frontiers in Neurology.2025;[Epub] CrossRef - Awareness and Practice of Global Cancer Prevention Dietary Guidelines among Koreans
Ahyoung Yun, Yoonjoo Choi, Hyein Jung, Byungmi Kim
Journal of Cancer Prevention.2025; 30(1): 32. CrossRef - Incidences of secondary malignancies after androgen deprivation therapy for prostate cancer
Junghoon Lee, Min Chul Cho, Hyeon Jeong, Hwancheol Son, Sangjun Yoo
Clinical Genitourinary Cancer.2025; : 102379. CrossRef - Trends in Epidemiology, Clinical Characteristics, and Outcomes of Infective Endocarditis: A 16-Year Nationwide Cohort Study in Korea
Kyung Eun Ha, William D Kim, Kyu-Yong Ko, Hasung Kim, Seo-Yeon Gwak, Kyu Kim, Hyun-Jung Lee, Chi Young Shim, Geu-Ru Hong, Jong-Won Ha, Ji-won Hwang, Iksung Cho
Journal of Korean Medical Science.2025;[Epub] CrossRef - Comparative Analysis of Chemotherapy‐Induced Oral Mucositis, Nutritional Status, and Depression in Patients With Acute Leukemia
Juhee Song, Hannah Yu, Eunjung Ryu, Liren Qian
European Journal of Cancer Care.2025;[Epub] CrossRef - The Impact of Small Area Level Deprivation on Colorectal Cancer Survival: Findings from the Regional Cancer Registry
S M Hong, K Changhoon, S Jang, A Kim, D U Kim, D H Baek, S H Lee, Y H Yi, H Park, J Lee, T I Kim, H J Lee
Endoscopy.2025; 57(S 02): S115. CrossRef - Impact of diagnosis-to-treatment interval on mortality in patients with early-stage breast cancer: a retrospective nationwide Korean cohort
Sung Hoon Jeong, Seong Min Chun, Hyunji Lee, Miji Kim, Ja-Ho Leigh
BMC Women's Health.2025;[Epub] CrossRef - Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience
Jiwon Koh, Jinyong Kim, Go-Un Woo, Hanbaek Yi, So Yean Kwon, Jeongmin Seo, Jeong Mo Bae, Jung Ho Kim, Jae Kyung Won, Han Suk Ryu, Yoon Kyung Jeon, Dae-Won Lee, Miso Kim, Tae-Yong Kim, Kyung-Hun Lee, Tae-You Kim, Jee-Soo Lee, Moon-Woo Seong, Sheehyun Kim,
Cancer Research and Treatment.2025; 57(2): 443. CrossRef - Outcomes following hypofractionated radiation therapy alone for surgically unfit early esophageal squamous cell carcinoma patients; a retrospective single center analysis
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Radiotherapy and Oncology.2024; 190: 109982. CrossRef - Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
Dong Jin Park, Tae Gyun Kwon, Jae Young Park, Jae Young Joung, Hong Koo Ha, Seong Soo Jeon, Sung-Hoo Hong, Sungchan Park, Seung Hwan Lee, Jin Seon Cho, Sung-Woo Park, Se Yun Kwon, Jung Ki Jo, Hong Seok Park, Sang-Cheol Lee, Dong Deuk Kwon, Sun Il Kim, San
The World Journal of Men's Health.2024; 42(3): 620. CrossRef - Adjustment to “new normal” after cancer among non–small cell lung cancer survivors: A qualitative study
Genehee Lee, Soo Yeon Kim, Alice Ahn, Sunga Kong, Heesu Nam, Danbee Kang, Hong Kwan Kim, Young Mog Shim, Ansuk Jeong, Dong Wook Shin, Juhee Cho
Palliative and Supportive Care.2024; 22(3): 487. CrossRef - Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea
Gang Kyu Kim, Young Heun Jo, Jongsoo Lee, Hyun Ho Han, Won Sik Ham, Won Sik Jang, Ji Eun Heo
Investigative and Clinical Urology.2024; 65(5): 435. CrossRef - Carbon footprint and cost reduction by endoscopic grading of gastric intestinal metaplasia using narrow‐band imaging
Jun‐Hyung Cho, So‐Young Jin, Suyeon Park
Journal of Gastroenterology and Hepatology.2024; 39(5): 942. CrossRef - Socioeconomic inequality of health-related quality of life in cancer survivors in South Korea
Sung Hoon Park
Supportive Care in Cancer.2024;[Epub] CrossRef - Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea
Yoon Hwan Byun, Johyun Ha, Ho Kang, Chul-Kee Park, Kyu-Won Jung, Heon Yoo
JCO Global Oncology.2024;[Epub] CrossRef - Machine learning-derived model for predicting poor post-treatment quality of life in Korean cancer survivors
Yu Hyeon Choe, Sujee Lee, Yooseok Lim, Soo Hyun Kim
Supportive Care in Cancer.2024;[Epub] CrossRef -
The interaction between magnesium intake, the genetic variant
INSR
rs1799817 and colorectal cancer risk in a Korean population: a case-control study
Linh Thi Dieu Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
International Journal of Food Sciences and Nutrition.2024; 75(4): 396. CrossRef - Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
Seong Cheol Kim, Seungbong Han, Ji Hyung Yoon, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Gyung-Min Park, Taekmin Kwon
Investigative and Clinical Urology.2024; 65(2): 124. CrossRef - Efficacy of biological inhibitors in three-dimensional culture models of oral squamous cell carcinoma
Eun Kyoung Kim, Sook Moon, Myung-Jin Lee, Dokyeong Kim
International Journal of Oral Biology.2024; 49(1): 18. CrossRef - Sex differences in inflammation correlated with estrogen and estrogen receptor-β levels in azoxymethane/dextran sodium sulfate-induced colitis-associated colorectal cancer mice
Seoyoung Jang, Hyejin Han, Yeonsoo Oh, Yuri Kim
Heliyon.2024; 10(6): e28121. CrossRef - Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case–control study in South Korea
Thi Tra Bui, Eunjung Park, Hee‐Yeon Kang, Jin‐Kyoung Oh
International Journal of Cancer.2024; 155(4): 654. CrossRef - Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
Chang Wook Jeong
Journal of Urologic Oncology.2024; 22(1): 4. CrossRef - A 42-year-old patient with renal cell carcinoma presenting as low back pain: A case report
Ga Yang Shim, Min-Su Kim, Hong Jun Kim, Yewan Park, So-Woon Kim, Myung Chul Yoo
Medicine.2024; 103(13): e37639. CrossRef - Association between Socioecological Status, Nutrient Intake, and Cancer Screening Behaviors in Adults Aged 40 and Over: Insights from the Eighth Korea National Health and Nutrition Examination Survey (KNHANES, 2019)
Seungpil Jeong, Yean-Jung Choi
Nutrients.2024; 16(7): 1048. CrossRef - Efficacy of high-protein diet protocol and education after distal gastrectomy for gastric cancer patients to prevent loss of lean body mass in Korea: a non-randomized controlled study
Hee Kyung Yoon, Sun Ae Kim, Ji Yoon Han, Dong Jin Kim
Annals of Clinical Nutrition and Metabolism.2024; 16(1): 10. CrossRef - Stigma and quality of life in lung cancer patients: The mediating effect of distress and the moderated mediating effect of social support
Hyewon Lim, Hyunmi Son, Gyumin Han, Taehwa Kim
Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100483. CrossRef - Direct gastric invasion from the liver metastasis of colorectal origin: A case report
Jun Yeb Nam, Jung Wook Lee, Jae Hyun Kim, Minjung Jung, Moo In Park, Won Moon, Sung Eun Kim, Kyoungwon Jung, Seun Ja Park
Medicine.2024; 103(15): e37732. CrossRef - Experiences of Patients With Breast Cancer Regarding Korean Medical Treatment Approaches: A Qualitative Study Protocol
Seungjin Noh, Yejin Hong, Jisu Ha, Sunjoong Kim, Inae Youn, Dongwoo Nam
International Journal of Qualitative Methods.2024;[Epub] CrossRef - Targeted Therapy of Advanced Non-Small Cell Lung Cancer
Yun-Gyoo Lee, Hyun-Il Gil, Soo Jeong Kim, Hyunjoo Lee, Heerim Nam, Soo-Youn Ham, Du-Young Kang
The Korean Journal of Medicine.2024; 99(2): 96. CrossRef - Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response
Moonki Hong, Sang Wook Lee, Byoung Chul Cho, Min Hee Hong, Sun Min Lim, Nak-Jung Kwon
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef - Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program
Se Hoon Park, Sang Joon Shin, Sun Young Rha, Seung-Hoon Beom, Ho Kyung Seo, Bhumsuk Keam, Miso Kim, Yoon-Hee Hong, Shinkyo Yoon, Jae-Lyun Lee
Frontiers in Oncology.2024;[Epub] CrossRef - Cancer-Associated Stroke: Thrombosis Mechanism, Diagnosis, Outcome, and Therapeutic Strategies
Ji Hoe Heo, Jaeseob Yun, Kwang Hyun Kim, Jae Wook Jung, Joonsang Yoo, Young Dae Kim, Hyo Suk Nam
Journal of Stroke.2024; 26(2): 164. CrossRef - Prognostic impact of intraoperative rupture in early-stage epithelial ovarian cancer: an ancillary study of GORILLA-3002
Eun Bi Jang, Eun Jung Yang, A Jin Lee, Hee Seung Kim, Suk-Joon Chang, Nam Kyeong Kim, Dong Hoon Suh, Sung Jong Lee, Yoo-Young Lee, Ji Eun Lee, Eun Ji Nam, Seung-Hyuk Shim
European Journal of Surgical Oncology.2024; 50(11): 108515. CrossRef - Exploring age-standardized cancer incidence rates and regional disparities: A retrospective cohort study of 8 major cancers in South Korea
Dagyeong Lee, Hye-won Yun, Nayeon Kim, Juwon Park, Kyu-won Jung, Mina Suh, Dong Wook Shin
Cancer Epidemiology.2024; 91: 102594. CrossRef - Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 2. Lung (non-small cell lung cancer)
Yoo-Kang Kwak, Kyung Su Kim, Gyu Sang Yoo, Hwa Kyung Byun, Yeon Joo Kim, Yeon-Sil Kim, Soo-Yoon Sung, Jin Ho Song, Byoung Hyuck Kim
Radiation Oncology Journal.2024; 42(2): 104. CrossRef - Novel diagnostic biomarkers for pancreatic cancer: assessing methylation status with epigenetic-specific peptide nucleic acid and KRAS mutation in cell-free DNA
Hongsik Kim, Jinah Chu, In-Gu Do, Yong-Pyo Lee, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Chinbayar Batochir, Eunji Jo, Kyo Rim Kim, Hye Sook Han
Frontiers in Oncology.2024;[Epub] CrossRef - Head and Neck Cancer: A Potential Risk Factor for Parkinson’s Disease?
Il Hwan Lee, Dong-Kyu Kim
Cancers.2024; 16(13): 2486. CrossRef - Problems and Alternatives for Korea National Lung Cancer Screening Program for Smoking Cessation: Analysis of a Survey Involving Experts
Cheol Min Lee, Sil Vi Han Park, Jinri Kim, Bumjo Oh, Kiheon Lee, Yeol Kim, Yu-Jin Paek
Journal of the Korean Society for Research on Nicotine and Tobacco.2024; 15(2): 49. CrossRef - Performance evaluation of the Allplex HPV HR Detection assay in comparison with the Cobas HPV test for high-risk HPV genotyping
Eun Hye Cho, Kangsu Shin, Min-Seung Park, Hee-Yeon Woo, Hyosoon Park, Min-Jung Kwon
Diagnostic Microbiology and Infectious Disease.2024; 110(2): 116433. CrossRef - Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
Jeong Eun Lee, Jin Hyun Nam, Sun Hong Kwon, Bo Kyung Kim, Seung Min Ha
Cancer Medicine.2024;[Epub] CrossRef - Systemic therapy for differentiated thyroid cancer with distant metastasis
Eun Kyung Lee
Journal of the Korean Medical Association.2024; 67(7): 484. CrossRef - Modifiable risk factors for weight loss after cancer treatment in Korean gastric cancer survivors
Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, BeLong Cho, Yun-Mi Song
Journal of Cancer Survivorship.2024;[Epub] CrossRef - Intracorporeal anastomosis in minimally invasive right hemicolectomy: a nationwide survey of the Korean Society of Coloproctology
Song Soo Yang, Bong Hyeon Kye, Sang Hee Kang, Chang Hyun Kim, Ji Hoon Kim, Woo Ram Kim, Kil Yeon Lee, In Kyu Park
Annals of Surgical Treatment and Research.2024; 107(2): 59. CrossRef - Data Resource Profile: The Cancer Public Library Database in South Korea
Dong-Woo Choi, Min Yeong Guk, Hye Ri Kim, Kwang Sun Ryu, Hyun-Joo Kong, Hyo Soung Cha, Hyun-Jin Kim, Heejung Chae, Young Sang Jeon, Hwanhee Kim, Jipmin Jung, Jeong-Soo Im, Kui Son Choi
Cancer Research and Treatment.2024; 56(4): 1014. CrossRef - Prognostic significance of serum creatinine and sarcopenia for 5-year overall survival in patients with colorectal cancer in Korea: a comparative study
Jiahn Choi, Hye Sun Lee, Jeonghyun Kang
Annals of Clinical Nutrition and Metabolism.2024; 16(2): 66. CrossRef - Disparities in Overall Survival Rates for Cancers across Income Levels in the Republic of Korea
Su-Min Jeong, Kyu-Won Jung, Juwon Park, Hyeon Ji Lee, Dong Wook Shin, Mina Suh
Cancers.2024; 16(16): 2923. CrossRef - Essential knowledge and technical tips for total mesorectal excision and related procedures for rectal cancer
Min Soo Cho, Hyeon Woo Bae, Nam Kyu Kim
Annals of Coloproctology.2024; 40(4): 384. CrossRef - Development and application of the mobile-based virtual nursing simulation training content: A mixed methods study
Hyun-Sun Kim, Jiyoung Kang
The Journal of Korean Academic Society of Nursing Education.2024; 30(3): 290. CrossRef - Helicobacter pylori infection facilitates cell migration and potentially impact clinical outcomes in gastric cancer
Ling Ou, Hengrui Liu, Chang Peng, Yuanjing Zou, Junwei Jia, Hui Li, Zhong Feng, Guimin Zhang, Meicun Yao
Heliyon.2024; 10(17): e37046. CrossRef - A higher dietary alpha-linolenic acid intake is associated with lower colorectal cancer risk based on MUC4 rs2246901 variant among Korean adults
Ha Thi Mien Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
Nutrition Research.2024; 131: 71. CrossRef - Colorectal Cancer and Obesity
Hyeong Ho Jo
Journal of Digestive Cancer Research.2024; 12(2): 82. CrossRef - Analysis of Dental Prosthetic Treatment in Patients with Cancer Aged 65 Years and Older after Expanded Health Insurance Coverage: A Retrospective Clinical Study
Hyo-Jung Kim, Iel-Yong Sung
Medicina.2024; 60(9): 1509. CrossRef - Dietary Calcium Intake and Colorectal Adenoma in Men and Women with Low Calcium Intake
Jioh Kang, Sang Hoon Kim, Joowon Chung, Dong Hyun Kim, Min Kyu Jung, Seun Ja Park, Hoon Jai Chun, Yun Jeong Lim, Hyun Jeong Cho, Jung Eun Lee
Journal of Digestive Cancer Research.2024; 12(2): 53. CrossRef - Epidemiological and Clinical Characteristics of Women Living with HIV in Korea
Sang Min Ahn, Yong Seop Lee, Min Han, Jung Ah Lee, Jae Eun Seong, Yae Jee Baek, JongHoon Hyun, Jung Ho Kim, Jin Young Ahn, Dong Hyun Oh, Su Jin Jeong, Ji Hyeon Baek, Nam Su Ku, Hee Kyoung Choi, Yoonseon Park, BumSik Chin, Young Keun Kim, Joon Sup Yeom, Yo
Infection & Chemotherapy.2024; 56(3): 369. CrossRef - Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi
Journal of Liver Cancer.2024; 24(2): 274. CrossRef - Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment
Eun Bi Jang, A Jin Lee, Kyeong A So, Sun Joo Lee, Ji Young Lee, Tae Jin Kim, Eunhyang Park, Soon-Beom Kang, Seung-Hyuk Shim
Gynecologic Oncology.2024; 191: 19. CrossRef - Comprehensive model for simultaneous monitoring of primary tumor to metastatic cancer utilizing Prkdc and Il2rg double knockout mice
Hee Jung Kwon, Jang Woo Park, Hye Kyung Chung, Joohee Jung
Scientific Reports.2024;[Epub] CrossRef - Incidence and pattern of second primary cancer in patients diagnosed with primary cancer
Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung
Oncology Letters.2024;[Epub] CrossRef - Serum bilirubin levels and risk of colorectal cancer in Korean adults: results from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort Study
Hwayoung Noh, Jeeyoo Lee, Nazlisadat Seyed Khoei, Laia Peruchet-Noray, Daehee Kang, Beatrice Fervers, Karl-Heinz Wagner, Aesun Shin, Heinz Freisling
British Journal of Cancer.2024; 131(10): 1635. CrossRef - Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy
Seung-been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
Cancer Research and Treatment.2024; 56(4): 1171. CrossRef - A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database
Joungyoun Kim, Yong-Hoon Kim, Yong-June Kim, Hee-Taik Kang
Journal of Personalized Medicine.2024; 14(10): 1058. CrossRef - FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi-An Kwon
Journal of Korean Medical Science.2024;[Epub] CrossRef - Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma
S.-Y. Jun, S. An, S.-M. Hong, J.-Y. Kim, K.-P. Kim
ESMO Open.2024; 9(11): 103969. CrossRef - Current perspectives on the pharmacological treatment of advanced
hepatocellular carcinoma: a narrative review
Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
The Ewha Medical Journal.2024;[Epub] CrossRef - Association of dietary manganese intake and the IL1R1 rs3917225 polymorphism with thyroid cancer risk: a prospective cohort study in Korea
Tao Thi Tran, Ha Thi Mien Nguyen, Madhawa Gunathilake, Jeonghee Lee, Jeongseon Kim
British Journal of Nutrition.2024; 132(12): 1584. CrossRef - TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer
Ju Yeon Pyo, Yoon Jin Cha, SoonWon Hong
Journal of Pathology and Translational Medicine.2024; 58(6): 310. CrossRef - Contrasting income-based inequalities in incidence and mortality of breast cancer in Korea, 2006-2015
Jinwook Bahk, Hee-Yeon Kang, Young-Ho Khang, Kyunghee Jung-Choi
Epidemiology and Health.2024; 46: e2024074. CrossRef - Metachronous Schnitzler’s Metastasis of Gastric Adenocarcinoma 13 Years After Curative Resection: A Case Report
Jun Kyeong Lim, Suk Bae Kim, Hyun Deok Shin
The Korean Journal of Gastroenterology.2024; 84(6): 282. CrossRef - Effectiveness of the Korean National Cancer Screening Program in Reducing Colorectal Cancer Mortality
Hyeon Ji Lee, Kyeongmin Lee, Byung Chang Kim, Jae Kwan Jun, Kui Son Choi, Mina Suh
Cancers.2024; 16(24): 4278. CrossRef - Use versus nonuse of antimicrobial prophylaxis prior to transperineal prostate biopsy: a propensity score-matched analysis
Dong Sup Lee, Seung-Ju Lee, Su Jin Kim, Je Mo Yoo, Young Hyo Choi, Hee Youn Kim
Prostate International.2024;[Epub] CrossRef - Genetically determined alcohol consumption and cancer risk in Korea
Keum Ji Jung, Ji Woo Baek, Sang Yop Shin, Sun Ha Jee
Epidemiology and Health.2023; 45: e2023077. CrossRef - Comparison of genetic variation between primary colorectal cancer and metastatic peritoneal cancer
Wonseok Shin, Jeongseok Yun, Kyudong Han, Dong-Guk Park
Genes & Genomics.2023; 45(8): 989. CrossRef - Precision Medicine in Head and Neck Cancer
Hye-sung Park, Jin-Hyoung Kang
Korean Society for Head and Neck Oncology.2023; 39(1): 1. CrossRef - Age-standardization and Standard Population
Dongui Hong, Sohyae Lee, Kyu-Won Jung, Aesun Shin
Journal of Health Informatics and Statistics.2023; 48(Suppl 1): S15. CrossRef - Changes in the Utilization of Health Care Services by Cancer Patients during the COVID-19 Pandemic
Seung Hee Seo, Sooyoung Cho, Shin Hye Yoo, Bhumsuk Keam, Aesun Shin
Yonsei Medical Journal.2023; 64(7): 463. CrossRef - Examining Final-Administered Medication as a Measure of Data Quality: A Comparative Analysis of Death Data with the Central Cancer Registry in Republic of Korea
Yae Won Tak, Jeong Hyun Han, Yu Jin Park, Do-Hoon Kim, Ji Seon Oh, Yura Lee
Cancers.2023; 15(13): 3371. CrossRef - Patterns of lymph node metastasis in esophageal carcinoma and their importance in esophageal cancer treatment
Dong Gue Shin
Foregut Surgery.2023; 3(2): 49. CrossRef - Outcomes of Fertility Preservation for Female Cancer Patients in a Single Tertiary Center
Ju Hee Kim, Hana Saeed Alzahrani, Sa Ra Lee, Sung Hoon Kim, Hee Dong Chae
Yonsei Medical Journal.2023; 64(8): 497. CrossRef - Association of Metformin Treatment with Risk for Death in Diabetic Patients with Concomitant Gastric Cancer
Jae-Hong Joo, Hyun-Soo Zhang, Jiyeon Chun, Eun-Cheol Park, Sohee Park
Cancers.2023; 15(16): 4134. CrossRef - Automated Detection of Gastric Lesions in Endoscopic Images by Leveraging Attention-Based YOLOv7
Sheeraz Ahmad, Jae-Seoung Kim, Dong Kyun Park, Taegkeun Whangbo
IEEE Access.2023; 11: 87166. CrossRef - ASAP1 Expression in Invasive Breast Cancer and Its Prognostic Role
Hosub Park, Hwangkyu Son, Hyebin Cha, Kihyuk Song, Seongsik Bang, Seungyun Jee, Hyunsung Kim, Jaekyung Myung, Su-Jin Shin, Chihwan Cha, Min Sung Chung, Seungsam Paik
International Journal of Molecular Sciences.2023; 24(18): 14355. CrossRef - Socioeconomic inequality in organized and opportunistic screening for gastric cancer: results from the Korean National Cancer Screening Survey 2009–2022
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kui Son Choi
Frontiers in Public Health.2023;[Epub] CrossRef - Trends in medical care utilization in patients with cancer: An analysis of real‐world data in a tertiary hospital in Korea, 2014–2019
Jung‐Hyun Won, Tae Kyu Chung, Joochul Lee, Sangwon Yoon, Yoomin Jeon, Howard Lee
Cancer Medicine.2023; 12(22): 21022. CrossRef - A Case of Complete Remission from Pancreatic Cancer Following Palliative Chemotherapy
Jae Jin Lee, Han Taek Jeong, June Hwa Bae
The Korean Journal of Pancreas and Biliary Tract.2023; 28(4): 131. CrossRef - Bilaterality as a Risk Factor for Recurrence in Papillary Thyroid Carcinoma
Hyeji Kim, Hyungju Kwon
Cancers.2023; 15(22): 5414. CrossRef - Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry
Bo Seong Yun, Eun Hye Park, Johyun Ha, Jung-Yun Lee, Keun Ho Lee, Taek Sang Lee, Kyung Ju Lee, Young Ju Kim, Kyu-Won Jung, Ju-Won Roh
Obstetrics & Gynecology Science.2023; 66(6): 545. CrossRef - Increased Risk of Alzheimer’s Disease in Patients with Head and Neck Cancer
Il Hwan Lee, Hyunjae Yu, Seung-Su Ha, Hee Gyu Yang, Dong-Kyu Kim
Cancers.2023; 15(23): 5516. CrossRef - Proton Pump Inhibitors and Likelihood of Colorectal Cancer in the Korean Population: Insights from a Nested Case–Control Study Using National Health Insurance Data
Mi Jung Kwon, Kyeong Min Han, Joo-Hee Kim, Ji Hee Kim, Min-Jeong Kim, Nan Young Kim, Hyo Geun Choi, Ho Suk Kang
Cancers.2023; 15(23): 5606. CrossRef - Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
Journal of Urologic Oncology.2023; 21(3): 217. CrossRef - Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, Sangchul Lee, Sung Kyu Hong, Seok Soo Byun, Jung Kwon Kim
Journal of Urologic Oncology.2023; 21(3): 200. CrossRef - Surgical outcomes and survival of patients over 80 years old who underwent curative resection for gastric cancer
Seunghui Lee, Miyeong Lee, Sangdon Kwan, Soohyung Kim, Ki Bum Park, Oh Kyoung Kwon, Ji Yeon Park
Annals of Surgical Treatment and Research.2023; 105(6): 376. CrossRef - Rare Neurological Complications in Thyroid Cancer Surgery
Joon Yong Park, Doh Young Lee
International Journal of Thyroidology.2023; 16(2): 143. CrossRef - Hormone Treatment for Breast Cancer
Suee Lee
The Korean Journal of Medicine.2023; 98(6): 283. CrossRef - The Impact of Neighborhood Deprivation on the Survival Rates of Patients with Cancer in Korea
Wonyoung Jung, Dong Wook Shin, Kyu-Won Jung, Dongjin Kim, Juwon Park, Fatima Nari, Mina Suh
Healthcare.2023; 11(24): 3171. CrossRef - Factors Associated with Poor Quality of Life in Breast Cancer Survivors: A 3-Year Follow-Up Study
Soo-Hyun Kim, Ha-Yeon Jo
Cancers.2023; 15(24): 5809. CrossRef - How should the healthcare system support cancer survivors? Survivors’ and health professionals’ expectations and perception on comprehensive cancer survivorship care in Korea: a qualitative study
Su Jung Lee, Dal-Lae Jin, Young Ae Kim, Hyun-Ju Seo, Seok-Jun Yoon
BMC Cancer.2023;[Epub] CrossRef - Regional disparities in major cancer incidence in Korea, 1999-2018
Eun Hye Park, Mee Joo Kang, Kyu-Won Jung, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Hyun-Joo Kong, Chang Kyun Choi, Jeong-Soo Im, Hong Gwan Seo
Epidemiology and Health.2023; 45: e2023089. CrossRef - Risk factors for early-onset lung cancer in Korea: analysis of a nationally representative population-based cohort
Jihun Kang, Taeyun Kim, Kyung-Do Han, Jin-Hyung Jung, Su-Min Jeong, Yo Hwan Yeo, Kyuwon Jung, Hyun Lee, Jong Ho Cho, Dong Wook Shin
Epidemiology and Health.2023; 45: e2023101. CrossRef
-
21,469
View
-
779
Download
-
122
Web of Science
-
138
Crossref
-
Prediction of Cancer Incidence and Mortality in Korea, 2023
-
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo
-
Cancer Res Treat. 2023;55(2):400-407.
-
DOI: https://doi.org/10.4143/crt.2023.448
-
-
Abstract
PDF
PubReader
ePub
- Purpose
This study aimed to report the projected cancer incidence and mortality for the year 2023 to estimate Korea’s current cancer burden.
Materials and Methods
Cancer incidence data from 1999 to 2020 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2021 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2023. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend.
Results
In total, 273,076 new cancer cases and 81,818 cancer deaths are expected to occur in Korea in 2023. The most common cancer site is expected to be the lung, followed by the thyroid, breast, colon and rectum, and stomach. These five cancers are expected to represent half of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and gallbladder cancers.
Conclusion
The incidence rates for all types of cancer in Korea are estimated to gradually decrease. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
-
Citations
Citations to this article as recorded by

- A Stool DNA-Based SDC2 Methylation Test for the Early Detection of Colorectal Cancer in an Asymptomatic, High-Risk Population: A Multicenter Prospective Randomized Trial
Chang Woo Kim, Hyunjin Kim, Hyoung Rae Kim, Daeyeon David Won, Woo Jung Nam, Byung Soh Min, Tae Jeong Oh, Sungwhan An, Suk-Hwan Lee
American Journal of Gastroenterology.2025; 120(3): 614. CrossRef - Efficacy and safety of herbal medicine treatment on postsurgical recovery in gastric cancer patients: A systematic review and meta-analysis
Soo-Dam Kim, Sook-Jin Pyo, Dong-Hyeon Kim, Hwa-Seung Yoo, So-Jung Park
Medicine.2025; 104(1): e41034. CrossRef - The efficacy of second‐line chemotherapy for advanced biliary tract cancer: A systematic review and network meta‐analysis
Inhwan Hwang, Sangah Han, Ji Hun Jeong, Chunhwa Ihm, Taeho Greg Rhee, Sung Ryul Shim
Journal of Hepato-Biliary-Pancreatic Sciences.2025; 32(4): 265. CrossRef - Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma
You-Na Sung
American Journal of Cancer Research.2025; 15(3): 1248. CrossRef - Advancements in Cancer Immunotherapy: The Evolution and Future of mRNA and DNA Vaccine Technologies
Kangchan Choi, Do Hyun Lee, Ji Won Lee, Yong Serk Park
Biomedical Science Letters.2025; 31(1): 1. CrossRef - Time-trend costs of infection-related cancers in Japan: a systematic review
Trinh Xuan Thi Nguyen, Sumeet Lal, Sulemana Abdul-Salam
Discover Public Health.2025;[Epub] CrossRef - A Mediating Effect of Psychological Distress in the Relationship Between Performance Status and Health-Related Quality of Life of Patients with Female Cancer
Eunha Yeo, JinShil Kim, Jisun Yang, Eun Young Park, Kwang-Hi Park, KyungAh Cho, Seongkum Heo
Healthcare.2025; 13(9): 1010. CrossRef - Anti-CHI3L1 antibody suppresses colon cancer growth through downregulation of VEGFA and NAMPT expression
Ji Won Seo, Deok Rim Heo, Ji Eun Yu, A-Young Nam, Na Yeong Lee, Ja Keun Koo, Sang Bae Han, Jung-Hyun Shim, Jin Tae Hong
Archives of Pharmacal Research.2025; 48(5): 450. CrossRef - Machine learning-derived model for predicting poor post-treatment quality of life in Korean cancer survivors
Yu Hyeon Choe, Sujee Lee, Yooseok Lim, Soo Hyun Kim
Supportive Care in Cancer.2024;[Epub] CrossRef - Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis
Hee Joong Lee, Banghyun Lee, Hangseok Choi, Minkyung Lee, Kyungjin Lee, Tae Kyoung Lee, Sung Ook Hwang, Yong Beom Kim
Cancers.2024; 16(4): 809. CrossRef - Feasibility of extracting cancer stage and metastasis codes from health insurance claims of outpatients and expressibility in ICD-11: a cross-sectional study using national health insurance data from South Korea
Young-Taek Park, Dongwoon Han, Kyoung-Hoon Kim, Hoguen Kim, Hojung Joseph Yoon, Chris Lane, Byeo-Ri Kim, Joo-Yeon Jeong
BMJ Open.2024; 14(2): e073952. CrossRef - A 42-year-old patient with renal cell carcinoma presenting as low back pain: A case report
Ga Yang Shim, Min-Su Kim, Hong Jun Kim, Yewan Park, So-Woon Kim, Myung Chul Yoo
Medicine.2024; 103(13): e37639. CrossRef - Biphasic Regulation of Apoptosis Following Gastric Irreversible Electroporation Using Tissue Immunohistochemistry of Activated Caspase-3 with TUNEL Method
Han Jo Jeon, Hoon Jai Chun, Hyuk Soon Choi, Bora Keum, Hong Bae Kim, Jong Hyuk Kim
Cancers.2024; 16(7): 1389. CrossRef - Association between Socioecological Status, Nutrient Intake, and Cancer Screening Behaviors in Adults Aged 40 and Over: Insights from the Eighth Korea National Health and Nutrition Examination Survey (KNHANES, 2019)
Seungpil Jeong, Yean-Jung Choi
Nutrients.2024; 16(7): 1048. CrossRef - Enhancing registration precision of multispectral breast images by fusing multi-wavelength information based on an improved gradient descent method
Gang Li, Jiatong Li, Meiling Fan, Nan Su Su Win, Ling Lin
Biomedical Signal Processing and Control.2024; 96: 106596. CrossRef - Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
Cancer Research and Treatment.2024; 56(3): 785. CrossRef - Extraperitoneal single-port robot-assisted radical prostatectomy: Short-term outcomes and technique description
Hyeok Jae Kwon, San Kang, Seung Ah Rhew, Chang Eil Yoon, Dongho Shin, Seokhwan Bang, Hyong Woo Moon, Woong Jin Bae, Hyuk Jin Cho, U-Syn Ha, Ji Youl Lee, Sae Woong Kim, Sung-Hoo Hong
Investigative and Clinical Urology.2024; 65(5): 442. CrossRef - Diagnostic Accuracy of Contrast-Enhanced Ultrasonography for the Assessment of Small Renal Mass: A Prospective Study
Jae-Wook Chung, Seo Young Park, Seunghee Woo, Yun Ah Kim, Jun-Koo Kang, Yun-Sok Ha, Jun Nyung Lee, Bum Soo Kim, Tae-Hwan Kim, Ghil Suk Yoon, Tae Gyun Kwon, See Hyung Kim
Journal of Urologic Oncology.2024; 22(2): 128. CrossRef - Modified Albumin-Bilirubin Grade After Curative Treatment: Predicting the Risk of Late Intrahepatic Recurrence of Hepatocellular Carcinoma
Myung Ji Goh, Hee Chul Park, Nalee Kim, Bong Kyung Bae, Moon Seok Choi, Jinsoo Rhu, Min Woo Lee, Woo Kyoung Jeong, Minji Kim, Kyunga Kim, Jeong Il Yu
Journal of Korean Medical Science.2024;[Epub] CrossRef - A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations
Eunbin Kwag, Soo-Dam Kim, Seong-Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa-Seung Yoo
Integrative Cancer Therapies.2024;[Epub] CrossRef - Psychometric Characteristics of the Fear of Cancer Recurrence Inventory-Severity Subscale Among Korean Cancer Survivors
So-Young Park
Journal of Preventive Medicine and Public Health.2024; 57(4): 319. CrossRef - Symptom burden, palliative care knowledge, and palliative care needs in advanced gynecological cancer patients in Korea
Eungil Ko, Yaelim Lee
Supportive Care in Cancer.2024;[Epub] CrossRef - An Antagonist Antibody That Inhibits Cancer Cell Growth In Vitro through RACK1
Ji Hoe Kim, Eun Ji Lee, Kyung Ho Han
Pharmaceuticals.2024; 17(10): 1303. CrossRef - Fish and meat intake in relation to colorectal adenoma in asymptomatic Korean adults
Young Sun Kim, Akinkunmi Paul Okekunle, Sun Young Yang, Ji Hyun Song, Jiyoung Youn, Gabby Yoon Jeong Kwon, Jung Eun Lee
Frontiers in Nutrition.2024;[Epub] CrossRef - The Past, Present and Future of Imaging Enhanced Endoscopy in Colon Tumor
Kyueng-Whan Min, One-Zoong Kim
Journal of Digestive Cancer Research.2024; 12(2): 90. CrossRef - Risk factor analysis and establishment of a predictive model for complications of elderly advanced gastric cancer with Clavien-Dindo classification ≥ II grade
Zhe-kui Liu, Wen-xing Ma, Jun-jie Zhang, Si-da Liu, Xiang-long Duan, Ze-zheng Wang
BMC Cancer.2024;[Epub] CrossRef - Social epidemiology of female breast cancer in the region of Varna-Bulgaria in 2013-2021 – A retrospective study
Galina Yaneva, Tsonka Dimitrova, Oskan Tasinov
F1000Research.2024; 13: 1137. CrossRef - The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Case–Control Study and a Prospective Study
Ga Hyun Lee, Yeon Hee Kim, Sang Myung Woo, Woo Jin Lee, Sung-Sik Han, Sang-Jae Park, Sherry Price, Penias Tembo, James R. Hébert, Mi Kyung Kim
Nutrients.2024; 16(22): 3941. CrossRef - Gold complexes: a new frontier in the battle against lung cancer
Aqsa Hanif, Sawsan S. Al-Rawi, Ahmad H. Ibrahim, Abbas Washeel Salman, Ayesha Zafar, Muhammad Adnan Iqbal, Sana Batool, Ghazanfar Abbas
Reviews in Inorganic Chemistry.2024;[Epub] CrossRef - LuminoMark: An Alternative for Localization
Ee Jin Kim, Tae Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
Journal of Surgical Innovation and Education.2024; 1(2): 46. CrossRef - High linc01116 expression may contribute to a poor prognosis in various cancers based on systematic reviews and meta-analyses
Si-Tong Fan, Dan Li, Qun-Xian Zhang, Li-Qiang Xu, Tao Zeng, Qiang Liu, Qiang Guo, Chen-Yi Lin, Wei-Min Luo
BMC Cancer.2024;[Epub] CrossRef - Application of Artificial Intelligence to Evaluate Thyroid Nodules
Jungmin Ahn, Myung-Chul Lee
Journal of Clinical Otolaryngology Head and Neck Surgery.2023; 34(2): 17. CrossRef - Outcomes of Fertility Preservation for Female Cancer Patients in a Single Tertiary Center
Ju Hee Kim, Hana Saeed Alzahrani, Sa Ra Lee, Sung Hoon Kim, Hee Dong Chae
Yonsei Medical Journal.2023; 64(8): 497. CrossRef - Artificial Intelligence in the Pathology of Gastric Cancer
Sangjoon Choi, Seokhwi Kim
Journal of Gastric Cancer.2023; 23(3): 410. CrossRef - Role of preoperative immunonutrition in patients with colorectal cancer: a narrative review
Soo Young Lee, Hyeung-min Park, Chang Hyun Kim, Hyeong Rok Kim
Annals of Clinical Nutrition and Metabolism.2023; 15(2): 46. CrossRef - Application of Acceptance and Commitment Therapy (ACT) in Hospice and Palliative Care Settings
So-Young Park
The Journal of Hospice and Palliative Care.2023; 26(3): 140. CrossRef - Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells
In-Seo Kwon, Yu-Na Hwang, Ju-Hee Park, Han-Heom Na, Tae-Hyung Kwon, Jin-Sung Park, Keun-Cheol Kim
International Journal of Molecular Sciences.2023; 24(23): 16621. CrossRef - Scalp nodules as the first presentation of prostate cancer: A CARE-compliant article
Tae Hoon Oh, Hun Soo Kim, Seung Chol Park
Medicine.2023; 102(50): e36570. CrossRef - Malignancy in Patients With Inborn Errors of Immunity Beyond Infectious Complication: Single Center Experience for 30 Years
Doo Ri Kim, Kyung-Ran Kim, Hwanhee Park, Joon-sik Choi, Yoonsun Yoon, Sohee Son, Hee Young Ju, Jihyun Kim, Keon Hee Yoo, Kangmo Ahn, Hee-Jin Kim, Eun-Suk Kang, Junhun Cho, Su Eun Park, Kihyun Kim, Yae-Jean Kim
Pediatric Infection & Vaccine.2023; 30(3): 129. CrossRef - Genetically determined alcohol consumption and cancer risk in Korea
Keum Ji Jung, Ji Woo Baek, Sang Yop Shin, Sun Ha Jee
Epidemiology and Health.2023; 45: e2023077. CrossRef
-
20,402
View
-
499
Download
-
41
Web of Science
-
40
Crossref
-
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021
-
Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, The Community of Population-Based Regional Cancer Registries
-
Cancer Res Treat. 2024;56(2):357-371. Published online March 13, 2024
-
DOI: https://doi.org/10.4143/crt.2024.253
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2021.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2021, with survival follow-up until December 31, 2022. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
The number of new cancer diagnoses in 2021 increased by 27,002 cases (10.8%) compared to 2020. In 2021, newly diagnosed cancer cases and deaths from cancer were reported as 277,523 (age-standardized rate [ASR], 289.3 per 100,000) and 82,688 (ASR, 67.6 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% from 2012 to 2015, thereafter, followed by non-significant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.8% from 2002 to 2013; 3.2% from 2013 to 2021). The 5-year relative survival between 2017 and 2021 was 72.1%, which contributed to prevalent cases reaching over 2.4 million in 2021.
Conclusion
In 2021, the number of newly diagnosed cancer patients increased as healthcare utilization recovered from the coronavirus disease 2019–related declines of 2020. Revised cancer registration guidelines expanded the registration scope, particularly for stomach and colorectal cancer. Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer control strategy. The long-term impact of the pandemic on cancer statistics requires future investigation.
-
Citations
Citations to this article as recorded by

- Determining risk‐adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors
Tung Hoang, Jeonghee Lee, So‐Youn Jung, Jeongseon Kim
International Journal of Cancer.2025; 156(9): 1692. CrossRef - Survivorship concerns among posttreatment cancer survivors in South Korea: A secondary analysis of a cross-sectional survey
Soo Hyun Kim
International Journal of Nursing Studies.2025; 162: 104982. CrossRef - Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study
Yun-Gyoo Lee, Dayeon Seo, Hyun-Il Gil, Dong-Hoe Koo, Suk Joong Oh
Annals of Hematology.2025;[Epub] CrossRef - Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
Journal of Gastric Cancer.2025; 25(1): 5. CrossRef - Sex Differences in Clinical Features and Survival Outcomes of Esophageal Cancer: A Comparative Study in the Korean Population
Jin Hee Noh, Hyungchul Park, Do Hoon Kim, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
The World Journal of Men's Health.2025;[Epub] CrossRef - Factors Influencing Postoperative Quality of Life in Korean Brain Tumor Survivors
Soomin Lim, Smi Choi-Kwon
Journal of Neuroscience Nursing.2025; 57(2): 74. CrossRef - A pharmacoinformatic approach for studying Atractylodes Lancea DC’s anticancer potential and control ROS-mediated apoptosis against prostate cancer cells
Chi-Hoon Ahn, Ji Soo Myong, Kazi Rejvee Ahmed, Md Ataur Rahman, Md. Maharub Hossain Fahim, Min Choi, Muntajin Rahman, Jinwon Choi, Kiryang Kim, Seungjoon Moon, Mohammed Dalli, Rony Abdi Syahputra, Sang-Won Shin, Abdel Halim Harrath, Moon Nyeo Park, Bongle
Frontiers in Oncology.2025;[Epub] CrossRef - Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do,
Blood Research.2025;[Epub] CrossRef - Dietary isoflavone intake among breast cancer survivors and cancer-free women
Sihan Song, Hyeong-Gon Moon, Dong-Young Noh, So-Youn Jung, Eun Sook Lee, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Young Bum Yoo, Se Kyung Lee, Jeong Eon Lee, Seok Jin Nam, Yoo Seok Kim, Jun Won Min, Shinyoung Jun, Hyojee Joung, Jung Eun Lee
Nutrition Research and Practice.2025; 19(1): 80. CrossRef - Return-to-Work Support Needs and Influencing Factors Among Korean Young Adult Cancer Survivors: A Cross-Sectional Study
Kisook Kim, Hyohyeon Yoon
Oncology Nursing Forum.2025; 52(2): 151. CrossRef - Principal component analysis and fine-tuned vision transformation integrating model explainability for breast cancer prediction
Huong Hoang Luong, Phuc Phan Hong, Dat Vo Minh, Thinh Nguyen Le Quang, Anh Dinh The, Nguyen Thai-Nghe, Hai Thanh Nguyen
Visual Computing for Industry, Biomedicine, and Art.2025;[Epub] CrossRef - Author's responses to “Comment on Kim (2025) ‘Survivorship concerns among posttreatment cancer survivors in South Korea: A secondary analysis of a cross-sectional survey’”
Soo Hyun Kim
International Journal of Nursing Studies.2025; 166: 105039. CrossRef - Post-gastrectomy anemia and ferritin dynamics: key determinants of prognosis and clinical management in patients with gastric cancer
Eun Young Kim, Kyo Young Song, Dong Jin Kim
Frontiers in Oncology.2025;[Epub] CrossRef - It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis
Nouhad El-Haddad, Yang Li, Geoff P. Delaney, Heewon Kang, Shalini Vinod, Margo Barr, Takahiro Tabuchi, Michael Kidd, Freddy Sitas
Cancer Epidemiology.2025; 96: 102775. CrossRef - A Urologist’s Perspective: Initial Experiences With SpaceOAR Hydrogel Insertion for Prostate Cancer Patients
Hyunho Han, Ik Jae Lee, Woong Sub Koom, Chan Woo Wee, Woong Kyu Han
Journal of Urologic Oncology.2025; 23(1): 20. CrossRef - Laparoscopic and robotic surgery for colorectal cancer in Korea: a nationwide health insurance database analysis from 2019 to 2023
Eun Ji Park, Hyun Gu Lee, Youn Young Park, Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee
Journal of Minimally Invasive Surgery.2025; 28(1): 25. CrossRef - Current status of endoscopy training for surgeons in Korea: a narrative review
Dae Kyung Sohn
Journal of Minimally Invasive Surgery.2025; 28(1): 1. CrossRef - Cancer risk according to lifestyle risk score trajectories: a population-based cohort study
Thi Minh Thu Khong, Thi Tra Bui, Hee-Yeon Kang, Eunjung Park, Moran Ki, Yoon-Jung Choi, Byungmi Kim, Jin-Kyoung Oh
BJC Reports.2025;[Epub] CrossRef - Mortality Risk According to Changes in Alcohol Consumption Post‐Diagnosis Among Liver Cancer Patients
Thi Tra Bui, Eunjung Park, Hee‐Yeon Kang, Byungmi Kim, Young‐Joo Won, Jin‐Kyoung Oh
Liver International.2025;[Epub] CrossRef - Plasma metabolite based clustering of breast cancer survivors and identification of dietary and health related characteristics: an application of unsupervised machine learning
Ga-Eun Yie, Woojin Kyeong, Sihan Song, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Jun Won Min, Yoo Seok Kim, Jung Eun Lee
Nutrition Research and Practice.2025; 19(2): 273. CrossRef - Time-trend costs of infection-related cancers in Japan: a systematic review
Trinh Xuan Thi Nguyen, Sumeet Lal, Sulemana Abdul-Salam
Discover Public Health.2025;[Epub] CrossRef - Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021
Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han
Annals of Surgical Oncology.2025;[Epub] CrossRef - Iron Consumption and Colorectal Cancer in Korean Adults: A Prospective Cohort Study
Sukhong Min, Katherine De la Torre, Hyobin Lee, Woo-Kyoung Shin, Daehee Kang
Nutrients.2025; 17(8): 1309. CrossRef - Diagnosis and Treatment of HER2-Positive Breast Cancer
Suee Lee
The Korean Journal of Medicine.2025; 100(2): 81. CrossRef - Evaluation of internal scatter contribution to gonadal dose in colorectal radiotherapy
Hyojun Park, Jung-In Kim, Chang Heon Choi, Jong Min Park, Seonghee Kang, Hyeongmin Jin, Eui Kyu Chie, Jaeman Son
Biomedical Physics & Engineering Express.2025; 11(3): 035009. CrossRef - Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
Journal of Liver Cancer.2025; 25(1): 109. CrossRef - Use of Pulmonary Rehabilitation for Lung Cancer Patients in Korea: Analysis of the National Health Insurance Service Database
Sang Hun Kim, Cho Hui Hong, Jong-Hwa Jeong, Jinmi Kim, Jeong Su Cho, Jin A Yoon, Jung Seop Eom, Byeong Ju Lee, Myung Hun Jang, Myung-Jun Shin, Yong Beom Shin
Journal of Korean Medical Science.2025;[Epub] CrossRef - Prediction of Cancer Incidence and Mortality in Korea, 2025
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Kui Son Choi, Han-Kwang Yang
Cancer Research and Treatment.2025; 57(2): 331. CrossRef - Colorectal Cancer Survivors' Inner Strength, Multiple Identities, and Quality of Life by Gender and Ostomy Presence: A Cross-Sectional Study
Hannah Yu, Eunjung Ryu
Korean Journal of Adult Nursing.2024; 36(2): 171. CrossRef - Chuna Manual Therapy or Electroacupuncture with Pregabalin for Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Pilot Study
Yeon-Woo Lee, Ilkyun Lee, Jin-Hyun Lee, Min-Geun Park, Ji-Hoon Kim, Yoon-Young Sunwoo, Man-Suk Hwang, Tae-Yong Park
Journal of Clinical Medicine.2024; 13(13): 3916. CrossRef - SMARCD3 Overexpression Promotes Epithelial–Mesenchymal Transition in Gastric Cancer
Sun Yi Park, Ji-Ho Park, Jung Wook Yang, Eun-Jung Jung, Young-Tae Ju, Chi-Young Jeong, Ju-Yeon Kim, Taejin Park, Tae-Han Kim, Miyeong Park, Young-Joon Lee, Sang-Ho Jeong
Cancers.2024; 16(12): 2282. CrossRef - Factors influencing psychological distress among breast cancer survivors using machine learning techniques
Jin-Hee Park, Misun Chun, Sun Hyoung Bae, Jeonghee Woo, Eunae Chon, Hee Jun Kim
Scientific Reports.2024;[Epub] CrossRef - The Influence of Professional Self-Concept and Patient Safety Culture on Burnout among Nurses in a Cancer Hospital
Soyoon Do, Eunjung Ryu
Asian Oncology Nursing.2024; 24(2): 53. CrossRef - Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas
Tae-Woo Kim, Kiyong Na, Junyang Jung, Heejin Lim, Hyewon Seo, Seung Hyeun Lee
Oncology.2024; 102(11): 969. CrossRef - Performance of the National Cancer Screening Program for Gastric Cancer in Korea
Young-Il Kim
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(3): 231. CrossRef - Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database
Chan Ho Lee, Minyong Kang, Cheol Kwak, Young Hwii Ko, Jung Kwon Kim, Jae Young Park, Seokhwan Bang, Seong Il Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Seock Hwan Choi, Joongwon Choi, Changil Choi, Se
Journal of Korean Medical Science.2024;[Epub] CrossRef - Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi
Journal of Liver Cancer.2024; 24(2): 274. CrossRef - Redefining the role of radiation therapy in pancreatic cancer management: innovations and future directions: A narrative review
Jeong Il Yu
Precision and Future Medicine.2024; 8(3): 74. CrossRef - A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database
Joungyoun Kim, Yong-Hoon Kim, Yong-June Kim, Hee-Taik Kang
Journal of Personalized Medicine.2024; 14(10): 1058. CrossRef - Longitudinal trajectories of frailty and cognitive decline among older Korean cancer survivors
Ran Won, Heesook Son, Jeehee Han, Youn-Jung Son
Geriatric Nursing.2024; 60: 636. CrossRef - Breast Cancer Statistics in Korea, 2021
Chihwan David Cha, Chan Sub Park, Hee-Chul Shin, Jaihong Han, Jung Eun Choi, Joo Heung Kim, Kyu-Won Jung, Sae Byul Lee, Sang Eun Nam, Tae In Yoon, Young-Joon Kang, Zisun Kim, So-Youn Jung, Hyun-Ah Kim
Journal of Breast Cancer.2024; 27(6): 351. CrossRef - Tobacco Use in Korea: Current Epidemiology and Public Health Issues
Jong Eun Park, Woo Min Jeong, Ye Jin Choi, So Young Kim, Kyoung Eun Yeob, Jong Hyock Park
Journal of Korean Medical Science.2024;[Epub] CrossRef - Endometrial cancer detected unusually after an ankle fracture secondary to severe anemia in an obese woman with heavy menstrual bleeding: A case report
Hyung Yoon, Tae Go, Kyung Kim, Yong Song, Dong Suh, Ki Kim
Molecular and Clinical Oncology.2024;[Epub] CrossRef - Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment
Eun Kyung Lee
International Journal of Thyroidology.2024; 17(2): 259. CrossRef - A Case Study of Korean Medicine in Treating Worsened Esophagitis Symptoms Following Anticancer Therapy in a Patient with Esophageal Cancer
Eun-seo Kim, Soo-min Jo, Si-young Song, Geun-jeong Kim, Young-su Lee
The Journal of Internal Korean Medicine.2024; 45(5): 895. CrossRef - The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
Jong Ho Park, Jong Jin Oh
Journal of Urologic Oncology.2024; 22(3): 246. CrossRef - Adherence to the Cancer Prevention Recommendations from World Cancer Research Fund/American Institute for Cancer Research After Cancer Diagnosis on Mortality in South Korea
Donghyun Won, Jeeyoo Lee, Sooyoung Cho, Ji Yoon Baek, Daehee Kang, Aesun Shin
Nutrients.2024; 16(23): 4049. CrossRef - Trends in Thyroid Cancer Mortality Rates in Korea: Insights from National Health Database
Won Gu Kim
Endocrinology and Metabolism.2024; 39(6): 853. CrossRef - Impact of Early Oral Feeding on Postoperative Outcomes after Elective Colorectal Surgery: A Systematic Review and Meta-Analysis
Soo Young Lee, Eon Chul Han
Digestive Surgery.2024; : 1. CrossRef - Nationwide Incidence Trends of Pediatric Parotid Malignancy in Korea and a Retrospective Analysis of Single-Institution Surgical Experience of Parotidectomy
Hyun Seong Kim, Seo Young Kim, Eun-Jae Chung, Seong Keun Kwon, Soon-Hyun Ahn, Yuh-Seog Jung, Jungirl Seok
Korean Society of Head and Neck Oncology.2024; 40(2): 7. CrossRef - Total gastrectomy patients had a lower diet volume and greater diet frequency than distal gastrectomy patients after 6 months
Ye-Ji Kim, Sang-Ho Jeong, Eun-Jung Jung, Taejin Park, Jin-Kwon Lee, Tae-Han Kim, Young-Hye Kim, Jae-Seok Min, Miyeong Park, Young-Joon Lee
Medicine.2024; 103(51): e40878. CrossRef - Quality of life outcomes in terminal cancer patients attending regional cancer centers in South Korea: protocol for a prospective cohort study
Jung hye Kwon, Jung Hun Kang, Jung-Sik Huh, Su-Jin Koh, Kyu-Hyoung Lim, Byungho Choi, Rock Bum Kim, Young Jin Choi, Eun-Kee Song, Hyun Woo Lee, Ye-Seul Kim, Se-Il Go, Hwan Jung Yun, Sun Jin Sym, Hyewon Ryu, Myung-won Lee
BMC Cancer.2024;[Epub] CrossRef - Beyond survival: a comprehensive review of quality of life in rectal cancer patients
Won Beom Jung
Annals of Coloproctology.2024; 40(6): 527. CrossRef - Post-colonoscopy Colorectal Cancer: Causes and Prevention
Jong Yoon Lee
Journal of Digestive Cancer Research.2024; 12(3): 160. CrossRef
-
12,183
View
-
569
Download
-
50
Web of Science
-
54
Crossref
Review Article
-
Clinical Circulating Tumor DNA Testing for Precision Oncology
-
Hyunji Kim, Kyoung Un Park
-
Cancer Res Treat. 2023;55(2):351-366.
-
DOI: https://doi.org/10.4143/crt.2022.1026
-
-
Abstract
PDF
PubReader
ePub
- Circulating tumor DNA (ctDNA) is the portion of the cell-free DNA in the blood of cancer patients released from tumor cells via apoptosis, necrosis, or active release. From 10 mL of blood, the 4-5 mL of plasma obtained from a cancer patient contains 5-10 ng/mL of ctDNA. The plasma contains not only ctDNA of tumor origin, but also DNA from normal cells or clonal hematopoiesis. Another characteristic of ctDNA is its rapid clearance from circulation; it has a half-life of 16 minutes to 2.5 hours. Obtaining reliable results from ctDNA requires the application and approval of standardized clinical validation guidelines; however, the status of numerous ctDNA tests currently varies. The clinical use of ctDNA testing should be carefully considered based on the test’s specific needs and characteristics. Here we provide the different characteristics of ctDNA tests and information regarding their validation and approval status.
-
Citations
Citations to this article as recorded by

- Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
Oluseyi Abidoye, Daniel H. Ahn, Mitesh J. Borad, Christina Wu, Tanios Bekaii-Saab, Sakti Chakrabarti, Mohamad Bassam Sonbol
Cells.2025; 14(3): 161. CrossRef - Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, Begoña P. Valderrama, Rosa Nadal
American Society of Clinical Oncology Educational Book.2025;[Epub] CrossRef - Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use?
Du-Bois Asante, Domenico Tierno, Gabriele Grassi, Bruna Scaggiante
International Journal of Molecular Sciences.2025; 26(5): 1889. CrossRef - Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Alexandra Bartolomucci, Monyse Nobrega, Tadhg Ferrier, Kyle Dickinson, Nivedita Kaorey, Amélie Nadeau, Alberto Castillo, Julia V. Burnier
npj Precision Oncology.2025;[Epub] CrossRef - Peritoneal Metastasis Mimicking Chemotherapy-Induced Complications in Lung Adenocarcinoma: A Diagnostic Challenge of a Case Report
Ryuichi Ohta, Kaoru Tanaka, Masayuki Miyata, Junko Tanizaki, Hidetoshi Hayashi
Cureus.2025;[Epub] CrossRef - Liquid Biopsy on Microfluidics: From Existing Endogenous to Emerging Exogenous Biomarkers Analysis
Xiaowen Ou, Peng Chen, Bi-Feng Liu
Analytical Chemistry.2025; 97(16): 8625. CrossRef - Search for Mutations Connected With Non‐Response to Anti‐EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours
Martina Čarnogurská, Valeriia Serhiivna Vasylieva, Táňa Macháčková, Marie Boudná, Lucie Pifková, Jana Orlíčková, Tina Catela Ivkovic, Ondrej Slabý, Beatrix Bencsiková, Vlad Popovici, Eva Budinská
Cancer Medicine.2025;[Epub] CrossRef - Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies
Nina Klimova, Sandra Close, David M. Kurtz, Richard D. Hockett, Laura Hyland
Oncotarget.2025; 16(1): 329. CrossRef - Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary
Philip N Papayanis, Cherry Au, Michael Jelinek, Alan Tan
BMJ Case Reports.2025; 18(5): e264469. CrossRef - The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology
Shaivy Malik, Sufian Zaheer
The Journal of Liquid Biopsy.2025; 8: 100299. CrossRef - Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view
Jakob M. Riedl, Florian Moik, Tamara Esterl, Sarah M. Kostmann, Armin Gerger, Philipp J. Jost
Virchows Archiv.2024; 484(2): 169. CrossRef - Routine molecular applications and recent advances in breast cancer diagnostics
Gabriella Pankotai-Bodó, Orsolya Oláh-Németh, Farkas Sükösd, Tibor Pankotai
Journal of Biotechnology.2024; 380: 20. CrossRef - liquid biopsy holds a promising approach for the early detection of cancer: Current information and future perspectives
Abdullah M. Shbeer, Ibrahim Ahmed Robadi
Pathology - Research and Practice.2024; 254: 155082. CrossRef - Internal Standards for Limit Controls and Absolute Abundance Measurement of Oncogenic Fusions and Mutations
Tom Morrison, Bryan Lo, Sophie J Deharvengt, Nick Lazaridis, Gregory J Tsongalis
The Journal of Applied Laboratory Medicine.2024; 9(1): 175. CrossRef - Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases
Aakash Desai, Lincoln W. Pasquina, Candice Nulsen, Rachel B. Keller-Evans, Douglas A. Mata, Hanna Tukachinsky, Geoffrey R. Oxnard
The Journal of Liquid Biopsy.2024; 4: 100140. CrossRef - Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management
Binliang Wang, Meng Wang, Ya Lin, Jinlan Zhao, Hongcang Gu, Xiangjuan Li
Clinical Chemistry and Laboratory Medicine (CCLM).2024; 62(11): 2111. CrossRef - The emerging role of liquid biopsy in oral squamous cell carcinoma detection: advantages and challenges
Sudha Gupta, Brijesh Singh, Rajul Abhishek, Sameer Gupta, Manisha Sachan
Expert Review of Molecular Diagnostics.2024; 24(4): 311. CrossRef - SERS biosensors for liquid biopsy towards cancer diagnosis by detection of various circulating biomarkers: current progress and perspectives
Nana Lyu, Amin Hassanzadeh-Barforoushi, Laura M. Rey Gomez, Wei Zhang, Yuling Wang
Nano Convergence.2024;[Epub] CrossRef - Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R.M. Black, Leora Horn, Jorge S. Reis-Filho, Charles Swanton
Trends in Cancer.2024; 10(7): 643. CrossRef - From Detection to Cure – Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer
Joshua A. Linscott, Hiroko Miyagi, Prithvi B. Murthy, Sijie Yao, G. Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M. Gilbert, Michael A. Poch, Wade J. Sexton, Philippe E. Spiess, Roger Li
Current Oncology Reports.2024; 26(8): 945. CrossRef - Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Cancer Research and Treatment.2024; 56(3): 721. CrossRef - Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside
Hashem O. Alsaab, Mohammad S. Alzahrani, Ammar A. Bahauddin, Bandar Almutairy
Archives of Biochemistry and Biophysics.2024; 758: 110066. CrossRef - Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies
Khadija Turabi, Kelsey Klute, Prakash Radhakrishnan
Cancers.2024; 16(13): 2432. CrossRef - Colorectal cancer screening: An update and South African perspective
VG Lala, A Mohamed, DJ Tate, NM Seabi, D Mokgoko
Wits Journal of Clinical Medicine.2024;[Epub] CrossRef - Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Journal of Pathology and Translational Medicine.2024; 58(4): 147. CrossRef - Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review
Margherita Ratti, Elena Orlandi, Ilaria Toscani, Stefano Vecchia, Elisa Anselmi, Jens Claus Hahne, Michele Ghidini, Chiara Citterio
Cancers.2024; 16(15): 2692. CrossRef - Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, Jose Munoz, Felipe Reyes-Cosmelli, Avivit Peer, Graham Cohen, Evan Y. Yu, Anja Lorch, Abhishek Bavle, Blanca Homet Moreno, Julia Markensohn, Mackenzie Edmondson, Cai Chen, Razvan Cristescu, Carol Peña, Jare
Nature Medicine.2024; 30(9): 2508. CrossRef - Is the development of liquid biopsy for the early detection and the monitoring of breast cancers on its way of overtaking mammography?
Hicham Mansour, Chakib Nejjari, Roberto Incitti, Naima Anouar, Abdelhak Ouhajjou
Frontiers in Medicine.2024;[Epub] CrossRef - Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges
Diletta Piana, Federica Iavarone, Elisa De Paolis, Gennaro Daniele, Federico Parisella, Angelo Minucci, Viviana Greco, Andrea Urbani
International Journal of Molecular Sciences.2024; 25(16): 8830. CrossRef - Latest Research Progress of Liquid Biopsy in Tumor—A Narrative Review
Hua Jiang
Cancer Management and Research.2024; Volume 16: 1031. CrossRef - Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
Carolina Reduzzi, Eleonora Nicolo’, Surbhi Singhal, Konstantinos Venetis, Ana Ortega-Franco, Diego de Miguel-Perez, Angelo Dipasquale, Mohamed A. Gouda, Erick F. Saldanha, Pashtoon M. Kasi, Eloisa Jantus-Lewintre, Nicola Fusco, Umberto Malapelle, David R.
Critical Reviews in Oncology/Hematology.2024; 203: 104483. CrossRef - The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, Martina Esposito, Maria Palmieri, Viola Bianca Serio, Diletta Rosati, Francesca Mari, Elisa Frullanti, Francesca Colombo
Cancers.2024; 16(16): 2882. CrossRef - New approach methodologies (NAMs) in drug safety assessment: A vision of the future
Ruth A. Roberts
Current Opinion in Toxicology.2024; 40: 100502. CrossRef - Prognostic Significance of Tumor and Inflammatory Markers in Disease-Free and Overall Survival Duration in Colonic Adenocarcinoma Patients
Mehmet Berksun Tutan, Kaan Canal, Orhan Aslan, İsmail Sezikli, Mahmut Arif Yüksek, Ramazan Topçu, Veysel Barış Turhan, Murat Kendirci, İbrahim Tayfun Şahiner
Cureus.2024;[Epub] CrossRef - Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
Loubna Omri, Marie Naigeon, Ronan Flippot, Javier Gavira-Díaz, Jesus Poveda-Ferriols, Dan Nguyen, Chaimae Abdi, Alvaro Arroyo-Salgado, Nathalie Chaput, Guillermo de Velasco, Laurence Albigès, Lucía Carril-Ajuria
Exploration of Targeted Anti-tumor Therapy.2024; 5(6): 1199. CrossRef - Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more
Timothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez, Vinay Prasad
BMJ Oncology.2024; 3(1): e000364. CrossRef - Clinical Applications of Circulating Tumor DNA Profiling in GI Cancers
Francesca Battaglin, Heinz-Josef Lenz
JCO Oncology Practice.2024; 20(11): 1481. CrossRef - The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
Epameinondas Koumpis, Vasileios Georgoulis, Konstantina Papathanasiou, Alexandra Papoudou-Bai, Panagiotis Kanavaros, Evangelos Kolettas, Eleftheria Hatzimichael
Biomedicines.2024; 12(12): 2658. CrossRef - Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases
Lama Dawi, Younes Belkouchi, Littisha Lawrance, Othilie Gautier, Samy Ammari, Damien Vasseur, Felix Wirth, Joya Hadchiti, Salome Morer, Clemence David, François Bidault, Corinne Balleyguier, Michèle Kind, Arnaud Bayle, Laila Belcaid, Mihaela Aldea, Claudi
Radiology.2024;[Epub] CrossRef - Introduction of Digital Polymerase Chain Reaction: Comparison with Real-time Polymerase Chain Reaction
Dongsup LEE
Korean Journal of Clinical Laboratory Science.2024; 56(4): 307. CrossRef - Predictive Value of Circulating Tumor DNA (ctDNA) and Neutrophil To Lymphocyte Ratio (NLR) in Patients with Colon and Gastric Cancer: Case Reports
Paul Șiancu, Monica Pătran , Ioana Dinu , Florina Buică , Monica Miron , Ana-Maria Dudău , Andreea-Elena Robu , Elena Palamariu , Ciprian Tănăsescu
Journal of Medical and Radiation Oncology.2024; 4(8): 61. CrossRef
-
11,452
View
-
493
Download
-
31
Web of Science
-
41
Crossref
Original Article
- Lung and Thoracic cancer
-
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
-
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
-
Cancer Res Treat. 2023;55(1):103-111. Published online June 20, 2022
-
DOI: https://doi.org/10.4143/crt.2022.264
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
-
Citations
Citations to this article as recorded by

- Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
International Journal of Obesity.2025; 49(1): 13. CrossRef - Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
Fabrice N. Njotu, Jessica Pougoue Ketchemen, Hanan Babeker, Nikita Henning, Anjong F. Tikum, Emmanuel Nwangele, Alissar Monzer, Nava Hassani, Brian D. Gray, Koon Y. Pak, Emina E. Torlakovic, Maruti Uppalapati, Humphrey Fonge
European Journal of Nuclear Medicine and Molecular Imaging.2025; 52(4): 1305. CrossRef - Interactions and communications in lung tumour microenvironment: chemo/radiotherapy resistance mechanisms and therapeutic targets
Yuan Feng, Ying Jiang, Lin Yang, Danni Lu, Ning Li, Qun Zhang, Haiyan Yang, Huiyuan Qin, Jiaxin Zhang, Xinyun Gou, Feng Jiang
Journal of Drug Targeting.2025; 33(6): 817. CrossRef - The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
Yanchao Luan, Chao Liang, Qingsong Han, Xueqin Zhou, Na Yang, li Zhao
BMC Cancer.2025;[Epub] CrossRef - Secretome and Proteome of Extracellular Vesicles Provide Protein Markers of Lung and Colorectal Cancer
Natalia Soloveva, Svetlana Novikova, Tatiana Farafonova, Olga Tikhonova, Victor Zgoda
International Journal of Molecular Sciences.2025; 26(3): 1016. CrossRef - Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
Lu Zheng, Yanzhu Bian, Yujing Hu, Congna Tian, Xinchao Zhang, Shuheng Li, Xin Yang, Yanan Qin
Frontiers in Medicine.2025;[Epub] CrossRef - Artificial intelligence-assisted point-of-care devices for lung cancer
Xin Jie Keith Ng, Anis Salwa Mohd Khairuddin, Hai Chuan Liu, Thian Chee Loh, Jiunn Liang Tan, Sook Mei Khor, Bey Fen Leo
Clinica Chimica Acta.2025; 570: 120191. CrossRef - Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients
Lanny Permatasari, Nadiya Afifah, Maryam Ishmatullah, Ruri Intania, Eli Halimah, Melisa Barliana
Cancer Management and Research.2025; Volume 17: 383. CrossRef - Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
Qi-An Wang, I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef - Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K. B. Gad, Katalin Dobra
Cancers.2025; 17(6): 986. CrossRef - Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain
Enric Carcereny, Manuel Domine, Ana Laura Ortega Granados
Frontiers in Oncology.2025;[Epub] CrossRef - Genomics and the early diagnosis of lung cancer
Francesco Pepe, Tancredi Didier Bazan Russo, Valerio Gristina, Andrea Gottardo, Giulia Busuito, Giuliana Iannì, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarl
Personalized Medicine.2025; : 1. CrossRef - Single-cell transcriptomics and machine learning unveil ferroptosis features in tumor-associated macrophages: Prognostic model and therapeutic strategies for lung adenocarcinoma
Ting Ji, Juanli Jiang, Xin Wang, Kai Yang, Shaojin Wang, Bin Pan
Frontiers in Pharmacology.2025;[Epub] CrossRef - Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression
Chen Chen, Ji Chen, Yanling Zhang, Qijun Zhang, Haixia Shi
Frontiers in Oncology.2025;[Epub] CrossRef - Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef - The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
Cancers.2024; 16(2): 417. CrossRef - Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
Cancers.2024; 16(3): 528. CrossRef - Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
Cancers.2024; 16(6): 1236. CrossRef - Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
International Journal of Cardiology.2024; 408: 132117. CrossRef - 18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
Cancers.2024; 16(14): 2525. CrossRef - Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
靖靖 丛
Advances in Clinical Medicine.2024; 14(07): 65. CrossRef - Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
Journal of Clinical Medicine.2024; 13(15): 4531. CrossRef - Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
Journal of Pain and Symptom Management.2024; 68(4): e325. CrossRef - Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
Cancers.2024; 16(15): 2661. CrossRef - Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
Cancers.2024; 16(15): 2765. CrossRef - The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
Shuang Li, Junting Chen, Baosen Zhou
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef - A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
ACS Applied Electronic Materials.2024;[Epub] CrossRef - miR-137: a potential therapeutic target for lung cancer
Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef - Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
European Journal of Medicinal Chemistry.2024; 280: 116952. CrossRef - CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
Cell & Bioscience.2024;[Epub] CrossRef - Methylation modification is a poor prognostic factor in non-small cell lung Cancer and regulates the tumor microenvironment: mRNA molecular structure and function
Kai Yang, YuPing Yang, Lin Yu, Fan Yang, YuXin Xiang, Jun Zeng, Na Huang
International Journal of Biological Macromolecules.2024; 282: 137214. CrossRef - Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer
June Yeop Lee, Joonseok Lee, Varissara Javakijkarnjanakul, Beatrice Chia-Sui Shih, Woohyun Jung, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
Journal of Chest Surgery.2024; 57(6): 511. CrossRef - M1 macrophage-related prognostic model by combining bulk and single-cell transcriptomic data in NSCLC
Liu Zhe, Liu Fang, Petinrin Olutomilayo Olayemi, Toseef Muhammad, Chen Nanjun, Zhu Zhongxu, Wong Ka-Chun
Exploration of Medicine.2024;[Epub] CrossRef - Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Michele Tomanelli, Federica Guffanti, Giulia Vargiu, Edoardo Micotti, Mara Rigamonti, Francesca Tumiatti, Elisa Caiola, Mirko Marabese, Massimo Broggini
Frontiers in Oncology.2024;[Epub] CrossRef - Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
International Journal of Molecular Sciences.2023; 24(5): 4881. CrossRef - Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275. CrossRef - Prior treated tuberculosis and mortality risk in lung cancer
Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
Frontiers in Medicine.2023;[Epub] CrossRef - All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef - Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
Scientific Reports.2023;[Epub] CrossRef - STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología (English Edition).2023; 76(12): 1003. CrossRef - A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
Healthcare.2023; 11(12): 1745. CrossRef - IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología.2023; 76(12): 1003. CrossRef - Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef - Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
Frontiers in Immunology.2023;[Epub] CrossRef
-
11,326
View
-
479
Download
-
55
Web of Science
-
44
Crossref
Review Article
-
HER2-Low Breast Cancer: Now and in the Future
-
Sora Kang, Sung-Bae Kim
-
Cancer Res Treat. 2024;56(3):700-720. Published online January 30, 2024
-
DOI: https://doi.org/10.4143/crt.2023.1138
-
-
Abstract
PDF
PubReader
ePub
- Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. “HER2-low” tumors, which exhibit a low level of HER2 expression (immunohistochemistry 1+ or 2+ without gene amplification), were conventionally considered not amenable to anti-HER2 targeting agents based on the results of a phase III trial of trastuzumab. However, this perspective is being challenged by the emergence of novel anti-HER2 antibody-drug conjugates, such as trastuzumab-deruxtecan. These innovative therapies have demonstrated remarkable efficacy against HER2-low breast cancer, shedding new light on a previously overlooked category of breast cancer. Such promising results highlight the need for in-depth investigations of the biology and prognostic implications of HER2-low tumors. In this review, we comprehensively summarize the current evidence surrounding this topic and highlight areas that warrant further exploration and research in the future.
-
Citations
Citations to this article as recorded by

- The impact of the new histological classification of breast cancer with the introduction of HER 2 low status
Myriam Doucet, Marion De Berti, Flavie Arbion, Caroline Goupille, Gilles Body, Lobna Ouldamer
Journal of Gynecology Obstetrics and Human Reproduction.2025; 54(4): 102928. CrossRef - Study on the Efficacy of HER-2
Expression in Neoadjuvant
Chemotherapy for HER2-Negative
Breast Cancer
伟康 于
Advances in Clinical Medicine.2025; 15(02): 1690. CrossRef - Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer
Sora Kang, Sung-Bae Kim
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef - MRI-based habitat analysis for Intratumoral heterogeneity quantification combined with deep learning for HER2 status prediction in breast cancer
Qing-Yu Li, Yue Liang, Lan Zhang, Jia-Hao Li, Bin-Jie Wang, Chang-Fu Wang
Magnetic Resonance Imaging.2025; 122: 110429. CrossRef - Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience
ılkay Cinar
Journal of International Medical Research.2025;[Epub] CrossRef - Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study
Yuting Li, Dan Han, Ting Hu, Jie Xiong, Yuehua Wang, Yanxia Zhao
Frontiers in Oncology.2025;[Epub] CrossRef
-
9,751
View
-
538
Download
-
4
Web of Science
-
6
Crossref
Special Article
-
Top Ten Lessons Learned from Trials in Oligometastatic Cancers
-
Vivian S. Tan, David A. Palma
-
Cancer Res Treat. 2023;55(1):5-14. Published online December 16, 2022
-
DOI: https://doi.org/10.4143/crt.2022.1460
-
-
Abstract
PDF
PubReader
ePub
- Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed. These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space.
-
Citations
Citations to this article as recorded by

- Quality of Life After Locoregional Treatment in Women with De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Camille Weiss, Philippe Trensz, Martin Schmitt, Massimo Lodi
Cancers.2025; 17(5): 751. CrossRef - Therapie bei oligometastasierten gastrointestinalen Tumoren
Thorsten Oliver Götze, Maximilian Kloft, Emmanouil Fokas, Thomas Schmidt, Hendrik Dapper
Die Onkologie.2025;[Epub] CrossRef - In situ generated CdTe quantum dot-encapsulated hafnium polymer membrane to boost electrochemiluminescence analysis of tumor biomarkers
Haiyin Li, Zhixin Wang, Feng Li, Panpan Gai
Analytical and Bioanalytical Chemistry.2024; 416(21): 4769. CrossRef - Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review
George J. Li, Hendrick Tan, Humza Nusrat, Joe Chang, Hanbo Chen, Ian Poon, Jeevin Shahi, May Tsao, Yee Ung, Patrick Cheung, Alexander V. Louie
International Journal of Radiation Oncology*Biology*Physics.2024; 120(2): 359. CrossRef - Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy
Adnan Danish, Alexandra Della Pia, Lindsay Fogel, Hassan Alkhatatneh, Charles Zhao, Tony Varughese, Karine A. Al Feghali, Lauren Pascual, Brittany Sinclaire, Michael Marafelias, Joshua Zenreich, Yen-Hong Kuo, Tatyana A. Feldman, Yi Zhang, Andre H. Goy, An
Frontiers in Oncology.2024;[Epub] CrossRef - Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma
Shereen Ezzat, Jesse D. Pasternak, Murali Rajaraman, Omar Abdel-Rahman, Andrée Boucher, Nicole G. Chau, Shirley Chen, Sabrina Gill, Martin D. Hyrcza, Nathan Lamond, Marie-Hélène Massicotte, Eric Winquist, Ozgur Mete
Frontiers in Oncology.2024;[Epub] CrossRef - Primary tumor resection in de novo metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis
Chen Wu, Xiang Li, Shiyang Liu, Litong Yao, Tianyi He, Yusong Wang, Haoran Dong, Shuyi Niu, Mozhi Wang, Yingying Xu
iScience.2024; 27(12): 111224. CrossRef - Oligometastasis: More Lessons to Be Learned
Kyung Hwan Kim, Yong Chan Ahn
Cancer Research and Treatment.2023; 55(1): 1. CrossRef - Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis
Chai Hong Rim, Won Kyung Cho, Sunmin Park, Won Sup Yoon, Dae Sik Yang
International Journal of Surgery.2023; 109(4): 1006. CrossRef - Re: Toni K. Choueiri, Thomas Powles, Laurence Albiges, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767–78
Clara Cerrato, Benjamin Pradere, Maria Carmen Mir
European Urology.2023; 84(4): e93. CrossRef - Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
Cancer Research and Treatment.2023; 55(4): 1063. CrossRef
-
9,247
View
-
445
Download
-
13
Web of Science
-
11
Crossref
Review Article
-
Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies
-
Hye-Young Min, Ho-Young Lee
-
Cancer Res Treat. 2023;55(3):720-736. Published online March 22, 2023
-
DOI: https://doi.org/10.4143/crt.2023.468
-
-
Abstract
PDF
PubReader
ePub
- Cancer is a leading cause of disease-related mortality worldwide. Drug resistance is one of the primary reasons for the failure of anticancer therapy. There are a number of underlying mechanisms for anticancer drug resistance including genetic/epigenetic modifications, microenvironmental factors, and tumor heterogeneity. In the present scenario, researchers have focused on these novel mechanisms and strategies to tackle them. Recently, researchers have recognized the ability of cancer to become dormant because of anticancer drug resistance, tumor relapse, and progression. Currently, cancer dormancy is classified into “tumor mass dormancy” and “cellular dormancy.” Tumor mass dormancy represents the equilibrium between cell proliferation and cell death under the control of blood supply and immune responses. Cellular dormancy denotes the state in which cells undergo quiescence and is characterized by autophagy, stress-tolerance signaling, microenvironmental cues, and epigenetic modifications. Cancer dormancy has been regarded as the stem of primary or distal recurrent tumor formation and poor clinical outcomes in cancer patients. Despite the insufficiency of reliable models of cellular dormancy, the mechanisms underlying the regulation of cellular dormancy have been clarified in numerous studies. A better understanding of the biology of cancer dormancy is critical for the development of effective anticancer therapeutic strategies. In this review, we summarize the characteristics and regulatory mechanisms of cellular dormancy, introduce several potential strategies for targeting cellular dormancy, and discuss future perspectives.
-
Citations
Citations to this article as recorded by

- The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S. W. Tan, Suresh S. Ramalingam, Caicun Zhou
Nature Reviews Clinical Oncology.2025; 22(2): 95. CrossRef - Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
Yu-Chan Chih, Amelie C. Dietsch, Philipp Koopmann, Xiujian Ma, Dennis A. Agardy, Binghao Zhao, Alice De Roia, Alexandros Kourtesakis, Michael Kilian, Christopher Krämer, Abigail K. Suwala, Miriam Stenzinger, Halvard Boenig, Agnieszka Blum, Victor Murcia P
Nature Communications.2025;[Epub] CrossRef - Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
Muhammad Tufail, Can-Hua Jiang, Ning Li
Military Medical Research.2025;[Epub] CrossRef - TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma
Shu Chen, Xi Zhang, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie
Communications Medicine.2025;[Epub] CrossRef - ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review)
Lokman Varisli, Panagiotis Zoumpourlis, Demetrios Spandidos, Vassilis Zoumpourlis, Spiros Vlahopoulos
Oncology Letters.2025; 29(5): 1. CrossRef - Apoptotic cell-derived extracellular vesicles-MTA1 confer radioresistance in cervical cancer by inducing cellular dormancy
Yuan-Run Deng, Qiao-Zhi Wu, Wan Zhang, Hui-Ping Jiang, Cai-Qiu Xu, Shao-Cheng Chen, Jing Fan, Sui-Qun Guo, Xiao-Jing Chen
Journal of Translational Medicine.2025;[Epub] CrossRef - Growth factor receptor plasticity drives therapeutic persistence of metastatic breast cancer
Mitchell Ayers, Marvis Monteiro, Aneesha Kulkarni, Julie W. Reeser, Emily Dykhuizen, Sameek Roychowdhury, Michael K. Wendt
Cell Death & Disease.2025;[Epub] CrossRef - A comprehensive transcriptome based meta-analysis to unveil the aggression nexus of oral squamous cell carcinoma
Soujanya J. Vastrad, Ganesan Rajalekshmi Saraswathy, Jagadish B. Dasari, Gouri Nair, Ashok Madarakhandi, Dominic Augustine, S.V. Sowmya
Biochemistry and Biophysics Reports.2025; 42: 102001. CrossRef - The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression
Hazel Reeva, Godson Mahesh, Uma Manjunath, Nagarajan Selvamurugan, Durairaj MohanKumar
Seminars in Oncology.2025; 52(3): 152346. CrossRef - Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation
Yaqing Zuo, Zhiwu Long, Rongrong Li, Yi Le, Silong Zhang, Huan He, Longjia Yan
European Journal of Medicinal Chemistry.2024; 265: 116106. CrossRef - Unveiling the role of cellular dormancy in cancer progression and recurrence
Evelyne Collignon
Current Opinion in Oncology.2024; 36(2): 74. CrossRef - Mitophagy-Mediated Tumor Dormancy Protects Cancer Cells from Chemotherapy
Yunqing Sun, Yang Chen, Zhenan Liu, Jingjing Wang, Junqiang Bai, Ruixue Du, Mingshu Long, Zhengjun Shang
Biomedicines.2024; 12(2): 305. CrossRef - Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis
Mengrui Yang, Yufeng Mu, Xiaoyun Yu, Dandan Gao, Wenfeng Zhang, Ye Li, Jingyang Liu, Changgang Sun, Jing Zhuang
Biomedicine & Pharmacotherapy.2024; 176: 116783. CrossRef - Colorectal cancer and dormant metastases: Put to sleep or destroy?
Marina A Senchukova
World Journal of Gastrointestinal Oncology.2024; 16(6): 2304. CrossRef - Tumor Dormancy and Reactivation: The Role of Heat Shock Proteins
Haneef Ahmed Amissah, Stephanie E. Combs, Maxim Shevtsov
Cells.2024; 13(13): 1087. CrossRef - Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview
Aiman Al-Ruwishan, Bushra Amer, Ahmed Salem, Ahmed Abdi, Namoonga Chimpandu, Abdelmonem Esa, Alexandros Melemenis, Muhammad Zubair Saleem, Roselit Mathew, Yaser Gamallat
Current Issues in Molecular Biology.2024; 46(8): 8340. CrossRef - Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways
Putri Cahaya Situmorang, Syafruddin Ilyas, Sony Eka Nugraha, Rony Abdi Syahputra, Nik Mohd Afizan Nik Abd Rahman
Frontiers in Pharmacology.2024;[Epub] CrossRef - Deciphering genetic and nongenetic factors underlying tumour dormancy: insights from multiomics analysis of two syngeneic MRD models of melanoma and leukemia
Marie-Océane Laguillaumie, Sofia Titah, Aurélie Guillemette, Bernadette Neve, Frederic Leprêtre, Pascaline Ségard, Faruk Azam Shaik, Dominique Collard, Jean-Claude Gerbedoen, Léa Fléchon, Lama Hasan Bou Issa, Audrey Vincent, Martin Figeac, Shéhérazade Seb
Biological Research.2024;[Epub] CrossRef - Deciphering Dormant Cells of Lung Adenocarcinoma: Prognostic Insights from O-glycosylation-Related Tumor Dormancy Genes Using Machine Learning
Chenfei Dong, Yang Liu, Suli Chong, Jiayue Zeng, Ziming Bian, Xiaoming Chen, Sairong Fan
International Journal of Molecular Sciences.2024; 25(17): 9502. CrossRef - Outcomes in ischemic and hemorrhagic stroke patients with cancer: The Japan Stroke Data Bank
Takeshi Yoshimoto, Kazunori Toyoda, Sohei Yoshimura, Shinichi Wada, Masafumi Ihara, Junji Miyazaki, Kaori Miwa, Tomohide Yoshie, Yoshihiro Miyamoto, Shotai Kobayashi, Kazuo Minematsu, Masatoshi Koga
Journal of the Neurological Sciences.2024; 466: 123234. CrossRef - Effect of postsurgical adjuvant chemotherapy timing on outcomes in patients with pancreatic cancer – a systematic review and meta-analysis
Longlan Zhou, Lin Zhang
Journal of Chemotherapy.2024; : 1. CrossRef - Apolipoproteins have a major role in cellular tumor dormancy in triple negative breast cancer: In-silico study
Zaynab El-Gammal, Usama Bakry, Ahmed F. El-Sayed, Toka A. Ahmed, Gehad Atef Oura, Shimaa E. Elshenawy, Nagwa El-Badri, Amin F. Romany, Khaled Amer, Tarek Elnagdy, Osama Mahmoud Azmy, Tarek Taha Ahmed Ali
Scientific Reports.2024;[Epub] CrossRef - Synthesis, In Silico Prediction, and In Vitro Evaluation of Anti-tumor Activities of Novel 4'-Hydroxybiphenyl-4-carboxylic Acid Derivatives as EGFR Allosteric Site Inhibitors
Wurood A. Shihab, Ammar A. Razzak Kubba, Lubna H. Tahtamouni, Khaled M. Saleh, Mai F. AlSakhen, Sana I. Kanaan, Abdulrahman M. Saleh, Salem R. Yasin
Current Medicinal Chemistry.2024; 31(38): 6336. CrossRef - Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, Chaeuk Chung
Cancers.2024; 16(23): 3996. CrossRef - Cancer Cells in Sleep Mode: Wake Them to Eliminate or Keep Them Asleep Forever?
Wenjie Liu, Antal H. Kovacs, Jinqiang Hou
Cells.2024; 13(23): 2022. CrossRef - Redox regulation of cancer stem cells: Biology and therapeutic implications
Min Du, Jian Zhang, Max S. Wicha, Ming Luo
MedComm – Oncology.2024;[Epub] CrossRef - Cellular senescence and tumor dormancy at the crossroads of therapy resistance, metastasis and cancer stemness
Qurrat Ul Ain
Asia-Pacific Journal of Oncology.2024;[Epub] CrossRef - Activation of P38 MAPK Signaling Cascade is Linked with Clinical Outcomes and Therapeutic Responses in Human Cancers
Aleksandra Emelyanova, Marianna Zolotovskaia, Elena Poddubskaya, Aleksander Modestov, Anton Buzdin, Denis Kuzmin
Biochemistry (Moscow).2024; 89(12-13): 2155. CrossRef
-
9,115
View
-
431
Download
-
27
Web of Science
-
28
Crossref
Original Articles
- Gastrointestinal cancer
-
Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer
-
Dagyeong Lee, Junyong Choi, Hye Jeong Oh, In-Hye Ham, Sung Hak Lee, Sachiyo Nomura, Sang-Uk Han, Hoon Hur
-
Cancer Res Treat. 2023;55(1):167-178. Published online May 20, 2022
-
DOI: https://doi.org/10.4143/crt.2022.094
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Appropriate preclinical mouse models are needed to evaluate the response to immunotherapeutic agents. Immunocompetent mouse models have rarely been reported for gastric cancer. Thus, we investigated immunophenotypes and responses to immune checkpoint inhibitor (ICI) in immunocompetent mouse models using various murine gastric cancer cell lines.
Materials and Methods
We constructed subcutaneous syngeneic tumors with murine gastric cancer cell lines, YTN3 and YTN16, in C57BL/6J mice. Mice were intraperitoneally treated with IgG isotype control or an anti–programmed death-ligand 1 (PD-L1) neutralizing antibody. We used immunohistochemistry to evaluate the tumor-infiltrating immune cells of formalin-fixed paraffin-embedded mouse tumor tissues. We compared the protein and RNA expression between YTN3 and YTN16 cell lines using a mouse cytokine array and RNA sequencing.
Results
The mouse tumors revealed distinct histological and molecular characteristics. YTN16 cells showed upregulation of genes and proteins related to immunosuppression, such as Ccl2 (CCL2) and Csf1 (M-CSF). Macrophages and exhausted T cells were more enriched in YTN16 tumors than in YTN3 tumors. Several YTN3 tumors were completely regressed by the PD-L1 inhibitor, whereas YTN16 tumors were unaffected. Although treatment with a PD-L1 inhibitor increased infiltration of T cells in both the tumors, the proportion of exhausted immune cells did not decrease in the non-responder group.
Conclusion
We confirmed the histological and molecular features of cancer cells with various responses to ICI. Our models can be used in preclinical research on ICI resistance mechanisms to enhance clinical efficacy.
-
Citations
Citations to this article as recorded by

- Tubulointerstitial nephritis antigen-like 1 from cancer-associated fibroblasts contribute to the progression of diffuse-type gastric cancers through the interaction with integrin β1
Dagyeong Lee, In-Hye Ham, Hye Jeong Oh, Dong Min Lee, Jung Hwan Yoon, Sang-Yong Son, Tae-Min Kim, Jae-Young Kim, Sang-Uk Han, Hoon Hur
Journal of Translational Medicine.2024;[Epub] CrossRef - Safety and Efficacy of Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients with a PD-L1 Positive Status: A Case Report
Alexandra V. Avgustinovich, Olga V. Bakina, Sergey G. Afanas’ev, Liudmila V. Spirina, Alexander M. Volkov
Current Issues in Molecular Biology.2023; 45(9): 7642. CrossRef - Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer
Tae Hoon Kim, Dagyeong Lee, Hye Jeong Oh, In-Hye Ham, Dong Min Lee, Yulim Lee, Zhang Zhang, Ding Ke, Hoon Hur
Life Sciences.2023; 335: 122230. CrossRef
-
9,016
View
-
440
Download
-
5
Web of Science
-
3
Crossref
- Breast cancer
-
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
-
Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
-
Cancer Res Treat. 2023;55(2):531-541. Published online September 7, 2022
-
DOI: https://doi.org/10.4143/crt.2022.221
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2)-targeted treatments. In this study, we investigated whether PIK3CA mutations were correlated with treatment response or duration in patients with HER2-positive (HER2+) breast cancer.
Materials and Methods
We retrospectively reviewed the clinical information of patients with HER2+ breast cancer who received HER2-targeted therapy for early-stage or metastatic cancers. The pathologic complete response (pCR), progression-free survival (PFS), and overall survival were compared between patients with wild-type PIK3CA (PIK3CAw) and those with mutated PIK3CA (PIK3CAm). Next-generation sequencing was combined with examination of PFS associated with anti-HER2 monoclonal antibody (mAb) treatment.
Results
Data from 90 patients with HER2+ breast cancer were analyzed. Overall, 34 (37.8%) patients had pathogenic PIK3CA mutations. The pCR rate of the PIK3CAm group was lower than that of the PIK3CAw group among patients who received neoadjuvant chemotherapy for early-stage cancer. In the metastatic setting, the PIK3CAm group showed a significantly shorter mean PFS (mPFS) with first-line anti-HER2 mAb. The mPFS of second-line T-DM1 was lower in the PIK3CAm group than that in the PIK3CAw group. Sequencing revealed differences in the mutational landscape between PIK3CAm and PIK3CAw tumors.
Conclusion
Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA. Precise targeted-therapy is needed to improve survival of patients with HER2+/PIK3CAm breast cancer.
-
Citations
Citations to this article as recorded by

- Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms
Whitney L. Hensing, Emily L. Podany, James J. Sears, Shaili Tapiavala, Andrew A. Davis
Oncotarget.2025; 16(1): 11. CrossRef - The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions
Young-Bin Cho, Kyoung-Sik Park
Medicina.2025; 61(3): 518. CrossRef - High frequency of the PIK3CA H1047L mutation in Indonesian breast cancer across molecular subtypes
Yan Wisnu Prajoko, Didik Setyo Heriyanto, Bayu Tirta Dirja, Susanto Susanto, Vincent Lau, Andrew Nobiantoro Gunawan, Brigitta Natasya Halim, Nur Dina Amalina, Rashi Kalra
PLOS One.2025; 20(5): e0322154. CrossRef - PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?
Ana Tomás, Marta Pojo
International Journal of Molecular Sciences.2025; 26(11): 5276. CrossRef - Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
Tatyana N. Sokolova, Grigory A. Yanus, Svetlana N. Aleksakhina, Yana V. Belysheva, Aleksandra P. Chernyakova, Yulia S. Zharnakova, Alisa S. Nikitina, Tatyana M. Stebneva, Aleksandr S. Martianov, Alla Yu. Goryainova, Mark I. Gluzman, Rashida V. Orlova, Ana
Cancers.2025; 17(11): 1833. CrossRef - Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis
Qian Ma, Bai Wei, Bi-Cheng Wang, Ganxin Wang, Xuan Zhou, Yan Wang
Oncology Letters.2024;[Epub] CrossRef - A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis
Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri
Breast Disease.2024; 43(1): 213. CrossRef - Liquid Biopsy in the Clinical Management of Cancers
Ho-Yin Ho, Kei-See (Kasey) Chung, Chau-Ming Kan, Sze-Chuen (Cesar) Wong
International Journal of Molecular Sciences.2024; 25(16): 8594. CrossRef - Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine
Eleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, Carolina Reduzzi, Massimo Cristofanilli
Current Opinion in Oncology.2024; 36(6): 503. CrossRef - Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer
Li Yin, Gui-lai Chen, Zhuo Xiang, Yu-lin Liu, Xing-yu Li, Jing-wang Bi, Qiang Wang
Biomedicine & Pharmacotherapy.2023; 162: 114648. CrossRef - Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
Scientific Reports.2023;[Epub] CrossRef - Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
Haizhu Chen, Xingbin Hu, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yao
Translational Oncology.2023; 37: 101738. CrossRef - Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, Jacques Raphael, Phillip Blanchette, Abdullah Al-Humiqani, Monali Ray
Cancers.2023; 15(17): 4336. CrossRef - The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita
Medical Oncology.2022;[Epub] CrossRef
-
8,723
View
-
310
Download
-
10
Web of Science
-
14
Crossref
Editorial
Original Articles
- Hematologic malignancy
-
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
-
Jinchul Kim, Jinhyun Cho, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim
-
Cancer Res Treat. 2023;55(3):1031-1047. Published online March 13, 2023
-
DOI: https://doi.org/10.4143/crt.2022.1658
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods
R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.
Results
Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion
Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.
-
Citations
Citations to this article as recorded by

- Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jean L. Koff, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Michele Stanchina, Sara Haddadi, Carla Casulo, Sabarish Ayyapp
Clinical Lymphoma Myeloma and Leukemia.2025; 25(4): e183. CrossRef - Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
Hanzala Ahmed Farooqi, Muhammad Saffi Ullah, Ahmed Raza, Zain Sadiq, Wardah Ali Shaikh, Rahmah Muhammad, Muhammad Shoaib Hussain
Critical Reviews in Oncology/Hematology.2025; 207: 104611. CrossRef - Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma
Abdur Jamil, Zaheer Qureshi, Rimsha Siddique, Faryal Altaf, Hamzah Akram, Rohma Jamil, Shehroz Aslam, Insija I. Selene
American Journal of Clinical Oncology.2025; 48(5): 262. CrossRef - Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef - Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
Xin-Zhuo Zhan, Yi-Wen Bo, Yu Zhang, Hai-Dong Zhang, Zhi-Hao Shang, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Wan-Zhou Zhao, Timo Teimonen, Tao Liu, Meng-Yi Lu, Ye Yang, Shan-Liang Sun, Hai-Wen Ni
Frontiers in Pharmacology.2025;[Epub] CrossRef - Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba, Chen Li
PLOS ONE.2024; 19(8): e0308247. CrossRef - Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma
Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao
Cancer Imaging.2024;[Epub] CrossRef - Targeting CD22 for B-cell hematologic malignancies
Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
Experimental Hematology & Oncology.2023;[Epub] CrossRef
-
8,345
View
-
680
Download
-
8
Web of Science
-
8
Crossref
-
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
-
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
-
Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022
-
DOI: https://doi.org/10.4143/crt.2022.008
-
-
Abstract
PDF
PubReader
ePub
- Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
-
Citations
Citations to this article as recorded by

- PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef - Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef - Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef - Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef
-
8,165
View
-
369
Download
-
3
Web of Science
-
4
Crossref
- Gastrointestinal cancer
-
Changes in Gut Microbiome upon Orchiectomy and Testosterone Administration in AOM/DSS-Induced Colon Cancer Mouse Model
-
Chin-Hee Song, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jae Young Jang, Ha-Na Lee
-
Cancer Res Treat. 2023;55(1):196-218. Published online July 1, 2022
-
DOI: https://doi.org/10.4143/crt.2022.080
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Sex hormones are known to affect the gut microbiota. Previously, we reported that endogenous and exogenous testosterone are associated with colorectal cancer (CRC) development and submucosal invasion. In the present study, we investigated whether the gut microbiota is affected by orchiectomy (ORX) and testosterone propionate (TP) administration using an azoxymethane/dextran sulfate sodium (AOM/DSS)-induced CRC mouse model.
Materials and Methods
Gut microbiota was evaluated by means of 16S rRNA gene sequencing of stool DNA extracted from feces that were obtained at 13 weeks after AOM injection (from 22-week-old animals) and stored in a gas-generating pouch.
Results
The increase in microbial diversity (Chao1 and Phylogenetic Diversity index) and Firmicutes/Bacteroidetes (F/B) ratio upon AOM/DSS treatment in ORX mice was significantly decreased by TP supplementation. The ratio of commensal bacteria to opportunistic pathogens was lower in the TP-administered females and ORX mice than in the AOM/DSS group. Opportunistic pathogens (Mucispirillum schaedleri or Akkermansia muciniphila) were identified only in the TP group. In addition, microbial diversity and F/B ratio were higher in male controls than in female and ORX controls. Flintibacter butyricus, Ruminococcus bromii, and Romboutsia timonensis showed similar changes in the male control group as those in the female and ORX controls.
Conclusion
In conclusion, testosterone determines the dysbiosis of gut microbiota, which suggests that it plays a role in the sex-related differences in colorectal carcinogenesis.
-
Citations
Citations to this article as recorded by

- The Role of Gut Microbiota Dysbiosis in Erectile Dysfunction: From Pathophysiology to Treatment Strategies
Aris Kaltsas, Ilias Giannakodimos, Eleftheria Markou, Konstantinos Adamos, Marios Stavropoulos, Zisis Kratiras, Athanasios Zachariou, Fotios Dimitriadis, Nikolaos Sofikitis, Michael Chrisofos
Microorganisms.2025; 13(2): 250. CrossRef - The Antioxidant and Chemopreventive Activity of a Nutraceutical Derived from Brassicaceae Seed Extracts for Colorectal Cancer
Ana Guzmán-Carrasco, Cristina Mesas, Kevin Doello, Jesús M. Porres, Alejandro García-Beltrán, Rosario Martínez, Francisco Bermúdez, Mercedes Peña, Consolación Melguizo, Jose Prados
Nutrients.2025; 17(8): 1358. CrossRef - AI for rapid identification of major butyrate-producing bacteria in rhesus macaques (Macaca mulatta)
Annemiek Maaskant, Donghyeok Lee, Huy Ngo, Roy C. Montijn, Jaco Bakker, Jan A. M. Langermans, Evgeni Levin
Animal Microbiome.2025;[Epub] CrossRef - Sex differences in colorectal cancer: with a focus on sex hormone–gut microbiome axis
Zihong Wu, Yuqing Huang, Renyi Zhang, Chuan Zheng, Fengming You, Min Wang, Chong Xiao, Xueke Li
Cell Communication and Signaling.2024;[Epub] CrossRef - Comparison of the fecal bacterial microbiota in mice, rats, and pigs after oral administration of alpha-glycosyl isoquercitrin
Hong Liu, Ryo Inoue, Mihoko Koyanagi, Shim-mo Hayashi, Gen Watanabe, Kentaro Nagaoka
The Journal of Toxicological Sciences.2024; 49(4): 151. CrossRef - Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics
Vineet Singh, Kanika Mahra, DaRyung Jung, Jae-Ho Shin
Probiotics and Antimicrobial Proteins.2024; 16(5): 1744. CrossRef - Role of sex steroids in colorectal cancer: pathomechanisms and medical applications
Jianglan Wu
American Journal of Cancer Research.2024; 14(7): 3200. CrossRef - Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals
Timur Liwinski, Matthias K. Auer, Johanna Schröder, Ina Pieknik, Christian Casar, Dorothee Schwinge, Lara Henze, Günter K. Stalla, Undine E. Lang, Alina von Klitzing, Peer Briken, Thomas Hildebrandt, Jeanne C. Desbuleux, Sarah V. Biedermann, Paul-Martin H
BMC Medicine.2024;[Epub] CrossRef - N-acyl glycines produced by commensal bacteria potentiate GLP-1 secretion as GPCR ligands
Anna Drzazga, Przemysław Bernat, Adriana Nowak, Marcin Szustak, Eliza Korkus, Edyta Gendaszewska-Darmach, Maria Koziołkiewicz
Biomedicine & Pharmacotherapy.2024; 180: 117467. CrossRef - Role of intestinal testosterone-degrading bacteria and 3/17β-HSD in the pathogenesis of testosterone deficiency-induced hyperlipidemia in males
Jun Tao, Wen Dai, Yongnan Lyu, Hang Liu, Juan Le, Ting Sun, Qian Yao, Zhiming Zhao, Xuejun Jiang, Yan Li
npj Biofilms and Microbiomes.2024;[Epub] CrossRef - Sexual dimorphism of gut microbiota in colorectal cancer
Zihong Wu, Ziming Wang, Jiamei Wang, Chong Xiao, Fengming You, Xueke Li
Chinese Science Bulletin.2024; 69(35): 5142. CrossRef - Direct and indirect effects of estrogens, androgens and intestinal microbiota on colorectal cancer
Zihong Wu, Yi Sun, Wenbo Huang, Zhenzhen Jin, Fengming You, Xueke Li, Chong Xiao
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef - From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes
Frances Widjaja, Ivonne M. C. M. Rietjens
Biomedicines.2023; 11(10): 2658. CrossRef - Murine models of colorectal cancer: the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of colitis-associated cancer
Dzhuliia Dzhalilova, Natalia Zolotova, Nikolai Fokichev, Olga Makarova
PeerJ.2023; 11: e16159. CrossRef
-
8,161
View
-
239
Download
-
16
Web of Science
-
14
Crossref
- Breast cancer
-
Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
-
Jieun Park, Soo Youn Cho, Eun Sol Chang, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Sung-Su Kim, Young Kee Shin, Yoon-La Choi
-
Cancer Res Treat. 2023;55(1):145-154. Published online April 20, 2022
-
DOI: https://doi.org/10.4143/crt.2022.001
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
The purpose of this study was to investigate the concordance rate of PIK3CA mutations between primary and matched distant metastatic sites in patients with breast cancer and to verify whether there are differences in the frequency of PIK3CA hotspot mutations depending on the metastatic sites involved.
Materials and Methods
Archived formalin-fixed paraffin-embedded (FFPE) specimens of primary breast and matched distant metastatic tumors were retrospectively obtained for 49 patients. Additionally, 40 archived FFPE specimens were independently collected from different breast cancer metastatic sites, which were limited to three common sites: the liver, brain, and lung. PIK3CA mutations were analyzed using droplet digital PCR, including hotspots involving exons 9 and 20.
Results
After analysis of 49 breast tumors with matched metastasis sites, 87.8% showed concordance in PIK3CA mutation status. According to PIK3CA hotspot mutation testing in 89 cases of breast cancer metastatic sites, the proportion of PIK3CA mutations at sites of metastasis involving the liver, brain, and lung was 37.5%, 28.6%, and 42.9%, respectively, which did not result in statistical significance.
Conclusion
The high concordance of PIK3CA mutation status between primary and matched metastasis sites suggests that metastatic sites, regardless of the metastatic organ, could be considered sample sources for PIK3CA mutation testing for improved therapeutic strategies in patients with metastatic breast cancer.
-
Citations
Citations to this article as recorded by

- Machine learning prediction of breast cancer local recurrence localization, and distant metastasis after local recurrences
Kristóf Attila Kovács, Csaba Kerepesi, Dalma Rapcsák, Lilla Madaras, Ákos Nagy, Anikó Takács, Magdolna Dank, Gyöngyvér Szentmártoni, Attila Marcell Szász, Janina Kulka, Anna Mária Tőkés
Scientific Reports.2025;[Epub] CrossRef - Prevalence and spectrum of PIK3 mutations in breast cancer and their correlation with clinicopathological features: A cross-sectional observational study from South India
HS Darling, Rahul Sud, Deep Kumar Raman
Cancer Research, Statistics, and Treatment.2025; 8(1): 39. CrossRef - Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer
Yue Wang, Xin Li, Shuang Zhang, Li Liang, Ling Xu, Yinhua Liu, Ting Li
Japanese Journal of Clinical Oncology.2024; 54(9): 1024. CrossRef - Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
Justus Rosin, Ella Svegrup, Antonios Valachis, Ioannis Zerdes
Breast Cancer Research and Treatment.2023; 201(2): 161. CrossRef - Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
Konstantinos Venetis, Francesco Pepe, Elisabetta Munzone, Elham Sajjadi, Gianluca Russo, Pasquale Pisapia, Mariia Ivanova, Giuseppina Bonizzi, Davide Vacirca, Alessandra Rappa, Alberto Ranghiero, Sergio Vincenzo Taormina, Giuseppe Viale, Giancarlo Troncon
Cells.2022; 11(22): 3545. CrossRef
-
7,875
View
-
310
Download
-
4
Web of Science
-
5
Crossref
- Lung and Thoracic cancer
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
-
Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
-
Cancer Res Treat. 2023;55(1):112-122. Published online July 19, 2022
-
DOI: https://doi.org/10.4143/crt.2022.381
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.
Materials and Methods
Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.
Results
A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.
Conclusion
Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.
-
Citations
Citations to this article as recorded by

- The importance of re-biopsy in the era of molecular therapy for lung cancer
Nensi Lalic, Daliborka Bursac, Marko Bojovic, Marko Nemet, Ivan Ergelasev
Srpski arhiv za celokupno lekarstvo.2024; 152(3-4): 209. CrossRef - Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi
Pathology.2024; 56(5): 653. CrossRef - Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer
Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Thoracic Cancer.2024; 15(19): 1513. CrossRef - Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
Ha-Lim Jeon, Meesong Kwak, Sohee Kim, Hye-Yeon Yu, Ju-Young Shin, Hyun Ae Jung
Scientific Reports.2024;[Epub] CrossRef - A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations
Eunbin Kwag, Soo-Dam Kim, Seong-Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa-Seung Yoo
Integrative Cancer Therapies.2024;[Epub] CrossRef - Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
Eun Hye Lee, Se Hyun Kwak, Kyeong Yeon Kim, Chi Young Kim, Sang Hoon Lee, Seok-Jae Heo, Yoon Soo Chang, Eun Young Kim
Frontiers in Oncology.2024;[Epub] CrossRef - Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
Qing Zhou, He-Long Zhang, Li-Yan Jiang, Yuan-Kai Shi, Yuan Chen, Jin-Ming Yu, Cai-Cun Zhou, Yong He, Yan-Ping Hu, Zong-An Liang, Yue-Yin Pan, Wen-Lei Zhuo, Yong Song, Gang Wu, Gong-Yan Chen, You Lu, Cui-Ying Zhang, Yi-Ping Zhang, Ying Cheng, Shun Lu, Chan
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10771. CrossRef
-
7,631
View
-
334
Download
-
9
Web of Science
-
7
Crossref
- Pediatric cancer
-
Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data
-
Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Park, Eu Jeen Yang, Young Tak Lim, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Meerim Park, Hyeon Jin Park, Byung-Kiu Park, Jun Ah Lee, Jun Eun Park, Soon Ki Kim, Ji Yoon Kim, Hyo Sun Kim, Youngeun Ma, Kyung Duk Park, Sang Kyu Park, Eun Sil Park, Ye Jee Shim, Eun Sun Yoo, Kyung Ha Ryu, Jae Won Yoo, Yeon Jung Lim, Hoi Soo Yoon, Mee Jeong Lee, Jae Min Lee, In-Sang Jeon, Hye Lim Jung, Hee Won Chueh, Seunghyun Won, the Korean Pediatric Hematology and Oncology Group (KPHOG)
-
Cancer Res Treat. 2023;55(1):279-290. Published online August 11, 2022
-
DOI: https://doi.org/10.4143/crt.2022.073
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.
Materials and Methods
From January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.
Results
Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).
Conclusion
The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.
-
Citations
Citations to this article as recorded by

- Hope and challenges in the diagnosis and treatment of Wilms tumor: a single-center retrospective study in China
Kongkong Cui, Peng Hong, Jie Lin, Zaihong Hu, Zhiqiang Gao, XiaoMao Tian, Tao Lin, Qinlin Shi, Guanghui Wei
Frontiers in Pediatrics.2025;[Epub] CrossRef - Loss of YTHDF1 suppresses the progression of malignant rhabdoid tumor of the kidney by regulating Glutathione S-transferase Mu 2 (GSTM2)
Qian-Wen Xiong, Yuntao Liu, Min He, Xiao-Die Shen, Manli Zhao, Shuang-Ai Liu, Gensheng Zhang, Qian Liu, Jinhu Wang, Wan-Xin Peng
Cell Biology and Toxicology.2025;[Epub] CrossRef - Congenital Mesoblastic Nephroma Mimic Wilms Tumor on 18F-FDG PET/CT and PET/MR
Wenzhu Hu, Chunxia Qin, Fuqiang Shao, Mengting Li, Xiaoli Lan
Clinical Nuclear Medicine.2024; 49(4): 353. CrossRef - Progress towards Therapies for Solid Renal Tumors in Children
洁 林
Advances in Clinical Medicine.2024; 14(06): 245. CrossRef
-
7,591
View
-
196
Download
-
3
Web of Science
-
4
Crossref
- General
-
Adherence to Cancer Prevention Guidelines and Cancer Incidence and Mortality: A Population-Based Cohort Study
-
Jin-Kyoung Oh, Minji Han, Byungmi Kim, Eun Young Park
-
Cancer Res Treat. 2023;55(1):15-27. Published online March 22, 2022
-
DOI: https://doi.org/10.4143/crt.2021.1031
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
This study aimed to estimate the risk of cancer incidence and mortality according to adherence to lifestyle-related cancer prevention guidelines.
Materials and Methods
Men and women who participated in the general health screening program in 2002 and 2003 provided by the National Health Insurance Service were included (n=8,325,492). Self-reported smoking, alcohol consumption, and physical activity habits and directly measured body mass index were collected. The participants were followed up until the date of cancer onset or death or 31 December 2018. The Cox proportional hazard model was used to evaluate the hazard ratio (HR) for cancer incidence and mortality according to different combinations of lifestyle behaviors.
Results
Only 6% of men and 15% of women engaged in healthy behavior at baseline, such as not smoking, not drinking alcohol, being moderately or highly physically active, and within a normal body mass index range. Compared to the best combination of healthy lifestyle behaviors, the weak and moderate associations with increased all cancer incidence (HR < 1.7) and mortality (HR < 2.5) were observed in those with heavy alcohol consumption and in former or current smokers. HRs of cancer mortality were significantly increased among current smokers in most combinations.
Conclusion
Compared to full adherence to cancer prevention recommendations, unhealthy behaviors increase cancer risk. As few people meet these recommendations, there is a great opportunity for cancer prevention.
-
Citations
Citations to this article as recorded by

- A comparative study of health behaviors in adult male cancer survivors and the general male population in Korea: from the Korea national health and nutrition examination survey VII-VIII (2016–2021)
Hyein Jung, Yoonjoo Choi, Byungmi Kim
Supportive Care in Cancer.2025;[Epub] CrossRef - Cancer risk according to lifestyle risk score trajectories: a population-based cohort study
Thi Minh Thu Khong, Thi Tra Bui, Hee-Yeon Kang, Eunjung Park, Moran Ki, Yoon-Jung Choi, Byungmi Kim, Jin-Kyoung Oh
BJC Reports.2025;[Epub] CrossRef - Increased risk of cardiovascular disease among kidney cancer survivors: a nationwide population-based cohort study
Minji Jung, Eunjung Choo, Shufeng Li, Zhengyi Deng, Jinhui Li, Mingyi Li, Satvir Basran, Sukhyang Lee, Marvin E. Langston, Benjamin I. Chung
Frontiers in Oncology.2024;[Epub] CrossRef - Cancer survivors’ adherence to the American cancer society and American institute of cancer research dietary guidelines in Lebanon
Jana Jabbour, Remie El Helou, Ruba Hadla, Riwa Azar, Maria Mezher, Farah Naja, Sally Temraz
BMC Public Health.2024;[Epub] CrossRef - Longitudinal Trends of Comorbidities and Survival Among Kidney Cancer Patients in Asian Population
Minji Jung, Eunjung Choo, Jinhui Li, Zhengyi Deng, Marvin E. Langston, Sukhyang Lee, Benjamin I. Chung
Cancer Medicine.2024;[Epub] CrossRef - Combinations of lifestyle behaviors and cancer risk among Korean adults
Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
Scientific Reports.2023;[Epub] CrossRef - Individual and joint effect of socioeconomic status and lifestyle factors on cancer in Korea
Chi Lan Tran, Kui Son Choi, Sun‐Young Kim, Jin‐Kyoung Oh
Cancer Medicine.2023; 12(16): 17389. CrossRef - Tumorkachexie: die Bedeutung von Ernährung und Bewegung in der Onkologie
Yurdagül Zopf, Hans Joachim Herrmann, Dejan Reljic, Luisa Marie Hardt
Zeitschrift für Komplementärmedizin.2023; 15(06): 12. CrossRef - Adherence to the World Cancer Research Fund/American Institute for Cancer Research and Korean Cancer Prevention Guidelines and cancer risk: a prospective cohort study from the Health Examinees-Gem study
Jeeyoo Lee, Aesun Shin, Woo-Kyoung Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee
Epidemiology and Health.2023; 45: e2023070. CrossRef
-
7,380
View
-
288
Download
-
7
Web of Science
-
9
Crossref
-
Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing–Based NTRK Fusion Detection in South Korea
-
Seung Eun Lee, Mi-Sook Lee, Yoon Kyung Jeon, Hyo Sup Shim, Jun Kang, Jihun Kim, Yoon-La Choi
-
Cancer Res Treat. 2023;55(1):28-40. Published online February 10, 2022
-
DOI: https://doi.org/10.4143/crt.2021.1572
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Tropomyosin receptor kinase (TRK) inhibitors are approved for the treatment of neurotrophic receptor tyrosine kinase (NTRK) fusion-positive tumors. The detection of NTRK fusion using a validated method is required before therapeutic application. An interlaboratory comparison study of next-generation sequencing (NGS)–based NTRK gene fusion detection with validated clinical samples was conducted at six major hospitals in South Korea.
Materials and Methods
A total of 18 samples, including a positive standard reference and eight positive and nine negative clinical samples, were validated using the VENTANA pan-TRK (EPR17341) and TruSight Oncology 500 assays. These samples were then tested using four different NGS panels currently being used at the six participating institutions.
Results
NTRK fusions were not detected in any of the nine negative clinical samples, demonstrating 100% specificity in all six participating institutions. All assays showed 100% analytical sensitivity to identify the NTRK fusion status in formalin-fixed paraffin-embedded (FFPE) samples, although with variable clinical sensitivity. False-negative results were due to low tumor purity, poor RNA quality, and DNA-based sequencing panel. The RNA-based targeted NGS assay showed an overall high success rate of identifying NTRK fusion status in FFPE samples.
Conclusion
This study is the first to test the proficiency of NGS-based NTRK detection in South Korea with the largest participating institutions. RNA-based NGS assays to detect NTRK fusions can accurately characterize fusion transcripts if sufficient RNA of adequate quality is available. The comparative performance data will support the implementation of targeted NGS-based sequencing assays for NTRK fusion detection in routine diagnostics.
-
Citations
Citations to this article as recorded by

- Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Susana Hernandez, Esther Conde, Aida Molero, Ana Suarez-Gauthier, Rebeca Martinez, Marta Alonso, Carlos Plaza, Carmen Camacho, Debora Chantada, Laura Juaneda-Magdalena, Enrique Garcia-Toro, Patricia Saiz-Lopez, Federico Rojo, Mar Abad, Valentina Boni, Sof
Archives of Pathology & Laboratory Medicine.2024; 148(3): 318. CrossRef - Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 4. Systemic Therapy for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer 2
Dong Yeob Shin, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Young Shin Song, Eun Kyung Lee, Dong-Jun Lim, Yun Jae Chung, Won Gu Kim
International Journal of Thyroidology.2024; 17(1): 168. CrossRef - CANTRK
Tracy L. Stockley, Bryan Lo, Adrian Box, Andrea Gomez Corredor, John DeCoteau, Patrice Desmeules, Harriet Feilotter, Daria Grafodatskaya, Wenda Greer, Cynthia Hawkins, Weei Yuarn Huang, Iyare Izevbaye, Guylaine Lépine, Sebastiao N. Martins Filho, Andreas
The Journal of Molecular Diagnostics.2023; 25(3): 168. CrossRef - NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas
Seung Eun Lee, Mi-Sook Lee, Heejin Bang, Mi Young Kim, Yoon-La Choi, Young Lyun Oh
Modern Pathology.2023; 36(8): 100180. CrossRef - Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
Moonsik Kim, Changseon Lee, Juyeon Hong, Juhee Kim, Ji Yun Jeong, Nora Jee-Young Park, Ji-Eun Kim, Ji Young Park
Cancer Research and Treatment.2023; 55(2): 429. CrossRef
-
7,349
View
-
318
Download
-
4
Web of Science
-
5
Crossref
- Hematologic malignancy
-
Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
-
Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim
-
Cancer Res Treat. 2023;55(1):291-303. Published online March 2, 2022
-
DOI: https://doi.org/10.4143/crt.2022.017
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).
Materials and Methods
After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.
Results
Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.
Conclusion
Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
-
Citations
Citations to this article as recorded by

- Clinical use of circulating tumor DNA analysis in patients with lymphoma
Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval
Human Pathology.2025; 156: 105679. CrossRef - Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef - Circulating tumor DNA in lymphoma: technologies and applications
Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
Journal of Hematology & Oncology.2025;[Epub] CrossRef - Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
Mohammad Almasri, Nawar Maher, Bashar Al Deeban, Ndeye Marie Diop, Riccardo Moia, Gianluca Gaidano
International Journal of Molecular Sciences.2025; 26(10): 4869. CrossRef - Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong, Yang Liu
Molecular Cancer.2024;[Epub] CrossRef - Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
Cancer Research and Treatment.2024; 56(3): 920. CrossRef - Minimal residual disease detection in lymphoma: methods, procedures and clinical significance
Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H. Young, Xudong Zhang
Frontiers in Immunology.2024;[Epub] CrossRef - Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
Blood Reviews.2024; 68: 101237. CrossRef - A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas
Laurence de Leval, Philippe Gaulard, Ahmet Dogan
Blood.2024; 144(18): 1855. CrossRef - In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
Jin Ju Kim, Hyun-Young Kim, Zisun Choi, So yoon Hwang, Hansol Jeong, Jong Rak Choi, Sang Eun Yoon, Won Seog Kim, Sun-Hee Kim, Hee-Jin Kim, Sang-Yong Shin, Seung-Tae Lee, Seok Jin Kim
Frontiers in Oncology.2023;[Epub] CrossRef - Circulating tumor DNA in NK/T and peripheral T cell lymphoma
Yu-Jia Huo, Wei-Li Zhao
Seminars in Hematology.2023; 60(3): 173. CrossRef - A genetic profiling guideline to support diagnosis and clinical management of lymphomas
Margarita Sánchez-Beato, Miriam Méndez, María Guirado, Lucía Pedrosa, Silvia Sequero, Natalia Yanguas-Casás, Luis de la Cruz-Merino, Laura Gálvez, Marta Llanos, Juan Fernando García, Mariano Provencio
Clinical and Translational Oncology.2023; 26(5): 1043. CrossRef
-
7,130
View
-
309
Download
-
12
Web of Science
-
12
Crossref
- Breast cancer
-
Diagnostic Assessment of Deep Learning Algorithms for Frozen Tissue Section Analysis in Women with Breast Cancer
-
Young-Gon Kim, In Hye Song, Seung Yeon Cho, Sungchul Kim, Milim Kim, Soomin Ahn, Hyunna Lee, Dong Hyun Yang, Namkug Kim, Sungwan Kim, Taewoo Kim, Daeyoung Kim, Jonghyeon Choi, Ki-Sun Lee, Minuk Ma, Minki Jo, So Yeon Park, Gyungyub Gong
-
Cancer Res Treat. 2023;55(2):513-522. Published online September 6, 2022
-
DOI: https://doi.org/10.4143/crt.2022.055
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Assessing the metastasis status of the sentinel lymph nodes (SLNs) for hematoxylin and eosin–stained frozen tissue sections by pathologists is an essential but tedious and time-consuming task that contributes to accurate breast cancer staging. This study aimed to review a challenge competition (HeLP 2019) for the development of automated solutions for classifying the metastasis status of breast cancer patients.
Materials and Methods
A total of 524 digital slides were obtained from frozen SLN sections: 297 (56.7%) from Asan Medical Center (AMC) and 227 (43.4%) from Seoul National University Bundang Hospital (SNUBH), South Korea. The slides were divided into training, development, and validation sets, where the development set comprised slides from both institutions and training and validation set included slides from only AMC and SNUBH, respectively. The algorithms were assessed for area under the receiver operating characteristic curve (AUC) and measurement of the longest metastatic tumor diameter. The final total scores were calculated as the mean of the two metrics, and the three teams with AUC values greater than 0.500 were selected for review and analysis in this study.
Results
The top three teams showed AUC values of 0.891, 0.809, and 0.736 and major axis prediction scores of 0.525, 0.459, and 0.387 for the validation set. The major factor that lowered the diagnostic accuracy was micro-metastasis.
Conclusion
In this challenge competition, accurate deep learning algorithms were developed that can be helpful for making a diagnosis on intraoperative SLN biopsy. The clinical utility of this approach was evaluated by including an external validation set from SNUBH.
-
Citations
Citations to this article as recorded by

- Detection of metastatic breast carcinoma in sentinel lymph node frozen sections using an artificial intelligence-assisted system
Chia-Ping Chang, Chih-Yi Hsu, Hsiang Sheng Wang, Peng-Chuna Feng, Wen-Yih Liang
Pathology - Research and Practice.2025; 267: 155836. CrossRef - Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer
Stefano Di Berardino, Nicolò Bizzarri, Marianna Ciancia, Francesca Moro, Belen Padial Urtueta, Claudia Marchetti, Gian Franco Zannoni, Giovanni Scambia, Anna Fagotti
International Journal of Gynecological Cancer.2025; : 101746. CrossRef - Comparing the diagnostic efficacy of optical coherence tomography and frozen section for margin assessment in breast-conserving surgery: a meta-analysis
Shishun Fan, Huirui Zhang, Zhenyu Meng, Ang Li, Yuqing Luo, Yueping Liu
Journal of Clinical Pathology.2024; 77(8): 517. CrossRef - Intraoperative Margin Assessment in Breast Conservation Surgery: A Necessity or a Luxury?
Srijan Shukla, Nisha Hariharan
Annals of Surgical Oncology.2023; 30(9): 5314. CrossRef
-
7,090
View
-
216
Download
-
3
Web of Science
-
4
Crossref
- Lung and Thoracic cancer
-
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
-
Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang
-
Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023
-
DOI: https://doi.org/10.4143/crt.2023.453
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.
-
Citations
Citations to this article as recorded by

- First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
Scientific Reports.2024;[Epub] CrossRef
-
6,983
View
-
595
Download
-
3
Web of Science
-
1
Crossref
Special Article
-
Prediction of Cancer Incidence and Mortality in Korea, 2024
-
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo
-
Cancer Res Treat. 2024;56(2):372-379. Published online March 11, 2024
-
DOI: https://doi.org/10.4143/crt.2024.252
-
-
Abstract
PDF
PubReader
ePub
- Purpose
This study aimed to report the projected cancer incidence and mortality for the year 2024 to estimate Korea’s current cancer burden.
Materials and Methods
Cancer incidence data from 1999 to 2021 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2022 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and multiplying the projected age-specific rates by the anticipated age-specific population for 2024. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend for prediction.
Results
In total, 292,221 new cancer cases and 83,770 cancer deaths are expected to occur in Korea in 2024. The most common cancer site is expected to be the thyroid, followed by the colon and rectum, lung, breast, and stomach. These five cancers are expected to represent 55.7% of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and stomach cancers.
Conclusion
The age-standardized incidence rates for female breast and prostate cancers are estimated to continue to increase. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
-
Citations
Citations to this article as recorded by

- Efficacy and safety of herbal medicine treatment on postsurgical recovery in gastric cancer patients: A systematic review and meta-analysis
Soo-Dam Kim, Sook-Jin Pyo, Dong-Hyeon Kim, Hwa-Seung Yoo, So-Jung Park
Medicine.2025; 104(1): e41034. CrossRef - Comparison of definitive radiotherapy outcomes between younger and older patients with high- or very-high-risk prostate cancer
Yong-Hyub Kim, Jae-Uk Jeong, Jung-Ho Yang, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Shinhaeng Cho, Sung-Ja Ahn
Radiotherapy and Oncology.2025; 205: 110763. CrossRef - Association Between Prostate Cancer Detection Rate and Year of Prostate Biopsy
Young Jun Uhm, Woojin Bang, Jae Hoon Chung, Cheol Young Oh, Hwanik Kim, Jin Seon Cho
Life.2025; 15(2): 260. CrossRef - Association between sedentary behavior, depressive symptoms, and the risk of all-cause and cause-specific mortality among U.S. cancer survivors
Ping Yao, Ying Zhong, Zhigong Wei
BMC Cancer.2025;[Epub] CrossRef - A Urologist’s Perspective: Initial Experiences With SpaceOAR Hydrogel Insertion for Prostate Cancer Patients
Hyunho Han, Ik Jae Lee, Woong Sub Koom, Chan Woo Wee, Woong Kyu Han
Journal of Urologic Oncology.2025; 23(1): 20. CrossRef - Regional population decline and health screening uptake in Korean adults: nationwide study using multilevel regression analysis
Wonjeong Jeong, Woorim Kim, Kyu-Tae Han
Frontiers in Public Health.2025;[Epub] CrossRef - Improved Prognostic Stratification With 2023 International Federation of Gynecology and Obstetrics Staging in Endometrial Cancer Reflecting Poor Prognosis of Aggressive Histological Types and p53 Abnormality
Miseon Lee, Heesoo Yoon, Ujae Kim, Jun Kang, Yeon Bi Han, Keun Ho Lee, Sung Jong Lee, Sook Hee Hong, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim, Ahwon Lee
Laboratory Investigation.2025; 105(9): 104189. CrossRef - Prognostic Significance of RBM3 Expression in Epithelial Ovarian Cancer: A Tissue Microarray-Based Study
Hyeong Chan Shin, Hye Won Lee, So-Jin Shin, Sun Young Kwon
Diagnostics.2025; 15(11): 1426. CrossRef - 2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
Eun Kyung Lee, Young Joo Park
Clinical Thyroidology®.2024; 36(4): 153. CrossRef - The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer
Seo Hee Choi, Seung-Hoon Beom, Young Deuk Choi, Won Sik Ham, Hyunho Han, Woong Kyu Han, Won Sik Jang, Seung Hwan Lee, Jaeho Cho
Cancers.2024; 16(18): 3159. CrossRef - Trend Analysis of Lung Cancer Incidence and Mortality in Xiamen (2011-2020)
Jianni Cong, Jiahuang Chi, Junli Zeng, Yilan Lin
Risk Management and Healthcare Policy.2024; Volume 17: 2375. CrossRef - The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Case–Control Study and a Prospective Study
Ga Hyun Lee, Yeon Hee Kim, Sang Myung Woo, Woo Jin Lee, Sung-Sik Han, Sang-Jae Park, Sherry Price, Penias Tembo, James R. Hébert, Mi Kyung Kim
Nutrients.2024; 16(22): 3941. CrossRef
-
6,934
View
-
314
Download
-
11
Web of Science
-
12
Crossref
Original Articles
- Lung and Thoracic cancer
-
Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
-
Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
-
Cancer Res Treat. 2023;55(1):83-93. Published online March 25, 2022
-
DOI: https://doi.org/10.4143/crt.2021.1571
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Previous report from the ASCEND-8 trial showed consistent efficacy with less gastrointestinal (GI) toxicity in patients with anaplastic lymphoma kinase-rearranged (ALK+) advanced/metastatic non–small cell lung cancer (NSCLC) treated with ceritinib 450-mg with food compared with 750-mg fasted. In this subgroup analysis, we report outcomes in Asian patients of the ASCEND-8 trial.
Materials and Methods
Key efficacy endpoints were blinded independent review committee (BIRC)–assessed overall response rate (ORR) and duration of response (DOR) evaluated per Response Evaluation Criteria in Solid Tumors v1.1. Other efficacy endpoints were investigator-assessed ORR and DOR; BIRC- and investigator-assessed progression-free survival (PFS) and disease control rate; overall survival (OS). Safety was evaluated by frequency and severity of adverse events.
Results
At final data cutoff (6 March 2020), 198 treatment-naïve patients were included in efficacy analysis, of which 74 (37%) comprised the Asian subset; 450-mg fed (n=29), 600-mg fed (n=19), and 750-mg fasted (n=26). Baseline characteristics were mostly comparable across study arms. At baseline, more patients in 450-mg fed arm (44.8%) had brain metastases than in 750-mg fasted arm (26.9%). Per BIRC, patients in the 450-mg fed arm had a numerically higher ORR, 24-month DOR rate and 24-month PFS rate than the 750-mg fasted arm. The 36-month OS rate was 93.1% in 450-mg fed arm and 70.9% in 750-mg fasted arm. Any-grade GI toxicity occurred in 82.8% and 96.2% of patients in the 450-mg fed and 750-mg fasted arms, respectively.
Conclusion
Asian patients with ALK+ advanced/metastatic NSCLC treated with ceritinib 450-mg fed showed numerically higher efficacy and lower GI toxicity than 750-mg fasted patients.
-
Citations
Citations to this article as recorded by

- Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India
Dharna Gupta, Nidhi Gupta, Navneet Singh, Shankar Prinja
JCO Global Oncology.2024;[Epub] CrossRef - Uniqueness of lung cancer in Southeast Asia
Vanita Noronha, Atul Budukh, Pankaj Chaturvedi, Srikanth Anne, Anshu Punjabi, Maheema Bhaskar, Tarini P. Sahoo, Nandini Menon, Minit Shah, Ullas Batra, Shrinidhi Nathany, Rajiv Kumar, Omshree Shetty, Trupti Pai Ghodke, Abhishek Mahajan, Nivedita Chakrabar
The Lancet Regional Health - Southeast Asia.2024; 27: 100430. CrossRef - Small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3 and TP53 mutations after distinct responses to tyrosine kinase inhibitors: A case report
Lingling Zhu, Yingchun Zhao, Yongqian Zhang, Zhai Liu, Wenhua Ma, Ying Guo, Qian Wang, Yan Guo, Hengxu Lv, Min Zhao
Heliyon.2024; 10(19): e38839. CrossRef
-
6,894
View
-
292
Download
-
2
Web of Science
-
3
Crossref
- Genitourinary cancer
-
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
-
Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park
-
Cancer Res Treat. 2023;55(2):636-642. Published online October 6, 2022
-
DOI: https://doi.org/10.4143/crt.2022.343
-
-
Abstract
PDF
PubReader
ePub
- Purpose
The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC).
Materials and Methods
In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety.
Results
Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates.
Conclusion
Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).
-
Citations
Citations to this article as recorded by

- Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma Using Amide Proton Transfer-Weighted MRI
Lingmin Kong, Bei Weng, Qian Cai, Ling Ma, Wenxin Cao, Yanling Chen, Long Qian, Yan Guo, Junxing Chen, Huanjun Wang
Academic Radiology.2025; 32(4): 2090. CrossRef - Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, Begoña P. Valderrama, Rosa Nadal
American Society of Clinical Oncology Educational Book.2025;[Epub] CrossRef - Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis
Hao Zhang
American Journal of Translational Research.2025; 17(1): 125. CrossRef - Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period
Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, Tao Xu
Annals of Surgical Oncology.2025;[Epub] CrossRef - The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer
Joseph Kattan, Clarisse Kattan, Fouad Aoun, Elie Nemr
Frontiers in Oncology.2025;[Epub] CrossRef - Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update
Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vasileios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis
Immunotherapy.2025; 17(6): 447. CrossRef - Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors
Xinya Wang, Qin Zhou, Xuyan Zhang, Han Hu, Binlei Liu, Yang Wang
Frontiers in Immunology.2025;[Epub] CrossRef - Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates
Takafumi Yanagisawa, Akihiro Matsukawa, Jeremy Yuen-Chun Teoh, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Paweł Rajwa, Fahad Quhal, Benjamin Pradere, Marco Moschini, Shahrokh F. Shariat, Jun Miki, Takahiro Kimura
Bladder Cancer.2025;[Epub] CrossRef - Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
Akihiro Matsukawa, Angelo Cormio, Marcin Miszczyk, Mehdi Kardoust Parizi, Tamás Fazekas, Ichiro Tsuboi, Stefano Mancon, Robert J. Schulz, Giulio Litterio, Ekaterina Laukhtina, Paweł Rajwa, Thomas Seisen, Keiichiro Mori, Francesca Sanguedolce, Andrea Bened
European Urology Oncology.2025;[Epub] CrossRef - Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
Shugo Yajima, Naoki Imasato, Hitoshi Masuda
BJUI Compass.2025;[Epub] CrossRef - Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Shibo Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Raoshan Luo, Weiming Liang
Frontiers in Immunology.2024;[Epub] CrossRef - What’s new about the tumor microenvironment of urothelial carcinoma?
João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo
Clinical and Translational Oncology.2024; 26(7): 1549. CrossRef - A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues
Yi Huang, Chengxiao Liao, Zefeng Shen, Yitong Zou, Weibin Xie, Qinghua Gan, Yuhui Yao, JunJiong Zheng, Jianqiu Kong
Frontiers in Immunology.2024;[Epub] CrossRef - Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
Clinical and Translational Oncology.2024; 26(7): 1759. CrossRef - Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Cancer Research and Treatment.2024; 56(3): 893. CrossRef - Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, M
New England Journal of Medicine.2024; 391(19): 1773. CrossRef - Klassische Chemotherapie, Immuntherapie oder adjuvante Strahlentherapie – Wie können wir die onkologischen Ergebnisse der radikalen Zystektomie verbessern?
Pia Paffenholz, Stefanie Zschäbitz
Die Urologie.2024; 63(10): 994. CrossRef - Recent developments in perioperative combination therapy in muscle-invasive bladder cancer
Jan-Jaap J. Mellema, Bas W.G. van Rhijn, Michiel S. van der Heijden
Current Opinion in Urology.2023; 33(5): 404. CrossRef
-
6,868
View
-
299
Download
-
16
Web of Science
-
18
Crossref
- Breast cancer
-
Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation
-
Ju Won Kim, Hyo Eun Kang, Jimi Choi, Seung Gyu Yun, Seung Pil Jung, Soo Yeon Bae, Ji Young You, Yoon-Ji Choi, Yeul Hong Kim, Kyong Hwa Park
-
Cancer Res Treat. 2023;55(1):155-166. Published online June 8, 2022
-
DOI: https://doi.org/10.4143/crt.2021.1567
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
BRCA1 and BRCA2 are among the most important genes involved in DNA repair via homologous recombination (HR). Germline BRCA1/2 (gBRCA1/2)-related cancers have specific characteristics and treatment options but conducting gBRCA1/2 testing and interpreting the genetic imprint are sometimes complicated. Here, we describe the concordance of gBRCA1/2 derived from a panel of clinical tumor tissues using next-generation sequencing (NGS) and genetic aspects of tumors harboring gBRCA1/2 pathogenic variants.
Materials and Methods
Targeted sequencing was performed using available tumor tissue from patients who underwent gBRCA1/2 testing. Comparative genomic analysis was performed according to gBRCA1/2 pathogenicity.
Results
A total of 321 patients who underwent gBRCA1/2 testing were screened, and 26 patients with gBRCA1/2 pathogenic (gBRCA1/2p) variants, eight patients with gBRCA1/2 variants of uncertain significance (VUS; gBRCA1/2v), and 43 patients with gBRCA1/2 wild-type (gBRCA1/2w) were included in analysis. Mutations in TP53 (49.4%) and PIK3CA (23.4%) were frequently detected in all samples. The number of single-nucleotide variants (SNVs) per tumor tissue was higher in the gBRCA1/2w group than that in the gBRCA1/2p group (14.81 vs. 18.86, p=0.278). Tumor mutation burden (TMB) was significantly higher in the gBRCA1/2w group than in the gBRCA1/2p group (10.21 vs. 13.47, p=0.017). Except for BRCA1/2, other HR-related genes were frequently mutated in patients with gBRCA1/2w.
Conclusion
We demonstrated high sensitivity of gBRCA1/2 in tumors analyzed by NGS using a panel of tumor tissues. TMB value and aberration of non-BRCA1/2 HR-related genes differed significantly according to gBRCA1/2 pathogenicity in patients with breast cancer.
-
Citations
Citations to this article as recorded by

- Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
Baijaeek Sain, Arnab Gupta, Aruni Ghose, Sudip Halder, Vishal Mukherjee, Samir Bhattacharya, Radha Raman Mondal, Aditya Narayan Sen, Bijan Saha, Shravasti Roy, Stergios Boussios
Journal of Personalized Medicine.2023; 13(5): 866. CrossRef
-
6,863
View
-
210
Download
-
1
Web of Science
-
1
Crossref
- Lung and Thoracic cancer
-
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
-
Beung-Chul Ahn, Ye-Jeong Han, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
-
Cancer Res Treat. 2023;55(2):488-497. Published online November 9, 2022
-
DOI: https://doi.org/10.4143/crt.2022.359
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
This study was conducted to investigate the clinical characteristics of patients with advanced non–small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) mutations and to evaluate response to standard treatment and HER2-targeted agents.
Materials and Methods
Using tissue and/or blood next-generation sequencing, we identified 44 patients with NSCLC harboring HER2 mutations who were treated at Severance Hospital between December 2016 and February 2021. Clinical data, including patient characteristics, mutation status, incidence of metastasis for distant lesions, and response to chemotherapy, were retrospectively analyzed.
Results
The median age was 58 years, and 61% of the patients were female. Most patients (64%) were never-smokers. Adenocarcinoma was the most predominant subtype (98%). A total of 66% of the patients had extrathoracic metastatic lesions, and 32% had intracranial lesions at initial presentation. The median time to the development of brain metastasis was 15.6 months (range, 2.4 to 43.7). The most common type of HER2 mutation was 12 base pair in-frame insertion in exon 20, A775_G776insYVMA. Of the 44 patients, two had concomitant driver mutations, one with epidermal growth factor receptor (EGFR) mutation (V769M), and one with BRAF mutation (V600E). Patients treated with pemetrexed-based chemotherapy (75%) had an overall response rate (ORR) and progression-free survival (PFS) of 30% and 8.3 months (95% confidence interval [CI], 3.9 to 12.7), respectively. The ORR and PFS of HER2-targeted agent treated patients (14%) were 0.0% and 1.9 months (95% CI, 0.1 to 2.8), respectively.
Conclusion
Given its distinct characteristics and treatment responses, novel treatment strategies for HER2-mutant NSCLC should be developed promptly to improve survival outcomes of patients.
-
Citations
Citations to this article as recorded by

- Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group
L. Decoster, D.R. Camidge, J.A. Fletcher, A. Addeo, A. Greystoke, K. Kantilal, L.Bigay Game, R. Kanesvaran, F. Gomes
Lung Cancer.2025; 200: 108087. CrossRef -
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With
HER2
Alterations: A Phase Ia Dose-Escalation Study
John V. Heymach, Frans Opdam, Minal Barve, Hai-Yan Tu, Yi-Long Wu, David Berz, Lukas Schröter, Yanick Botilde, Behbood Sadrolhefazi, Josep Serra, Kiyotaka Yoh, Noboru Yamamoto
Journal of Clinical Oncology.2025; 43(11): 1337. CrossRef - Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Daniel Reinhorn, Mor Moskovitz, William D. Tap, Bob T. Li
Cancer.2025;[Epub] CrossRef - Real-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer
Ruei-Lin Sun, Pei-Ya Liao, Ying-Ting Liao, Yi-Chen Yeh, Chi-Lu Chiang, Yuh-Min Chen, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Yen-Hsiang Huang, Yung-Hung Luo, Tsung-Ying Yang
Journal of the Chinese Medical Association.2025; 88(4): 307. CrossRef - Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Yating Hou, Xingyang Xue, Zhuoyun Zhang, Dahai Mai, Wei Luo, Mingyu Zhou, Zichuan Liu, Yisheng Huang
BMC Cancer.2025;[Epub] CrossRef - Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
Qian Zhang, Yehao Yang, Mingying Xie, Zichao Zhou, Haicheng Wu, Wanchen Zhai, Yunfei Chen, Kaiyan Chen, Shichao Zhou, Hui Li, Yun Fan
Lung Cancer.2025; 205: 108616. CrossRef - Prognostic factors in non-metastatic HER2 ‘low’ and HER2 ‘negative’ breast cancer: single institute experience
Alper Türkel, Mutlu Doğan, Elif Sertesen, Cengiz Karaçin, Sultan Çiğdem Irkkan, Öztürk Ateş
Wiener klinische Wochenschrift.2024; 136(11-12): 340. CrossRef - Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han
Modern Pathology.2024; 37(6): 100490. CrossRef - Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Meng Hu, Congying Zhong, Jiabing Wang, JinQin Chen, Tao Zhou
Frontiers in Immunology.2024;[Epub] CrossRef - Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis
Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Naohiro Watanabe, Yoshitsugu Horio, Yutaka Fujiwara
BMC Cancer.2024;[Epub] CrossRef - Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
David J. H. Bian, Sara F. Cohen, Anna-Maria Lazaratos, Nathaniel Bouganim, Matthew Dankner
Current Oncology.2024; 31(10): 6314. CrossRef - Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
Kelly Li, Ian Bosdet, Stephen Yip, Cheryl Ho, Janessa Laskin, Barbara Melosky, Ying Wang, Sophie Sun
Current Oncology.2023; 30(8): 7099. CrossRef
-
6,801
View
-
299
Download
-
12
Web of Science
-
12
Crossref
- Gastrointestinal cancer
-
Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer
-
Huan Peng, Jun Ying, Jia Zang, Hao Lu, Xiaokai Zhao, Pengmin Yang, Xintao Wang, Jieyi Li, Ziying Gong, Daoyun Zhang, Zhiguo Wang
-
Cancer Res Treat. 2023;55(4):1270-1280. Published online April 24, 2023
-
DOI: https://doi.org/10.4143/crt.2023.415
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
Loss-of-function mutations in the adenomatous polyposis coli (APC) gene are common in metastatic colorectal cancer (mCRC). However, the characteristic of APC specific mutations in mCRC is poorly understood. Here, we explored the clinical and molecular characteristics of N-terminal and C-terminal side APC mutations in Chinese patients with mCRC.
Materials and Methods
Hybrid capture-based next-generation sequencing was performed on tumor tissues from 275 mCRC pati-ents to detect mutations in 639 tumor-associated genes. The prognostic value and gene-pathway difference between APC specific mutations in mCRC patients were analyzed.
Results
APC mutations were highly clustered, accounting for 73% of all mCRC patients, and most of them were truncating mutations. The tumor mutation burden of the N-terminal side APC mutations group (n=76) was significantly lower than that of the C-terminal side group (n=123) (p < 0.001), further confirmed by the public database. Survival analysis showed that mCRC patients with N-terminus side APC mutations had longer overall survival than C-terminus side. Tumor gene pathway analysis showed that gene mutations in the RTK/RAS, Wnt and transforming growth factor β signaling pathways of the C-terminal group were significantly higher than those of the N-terminal group (p < 0.05). Additionally, KRAS, AMER1, TGFBR2, and ARID1A driver mutations were more common in patients with C-terminal side APC mutations.
Conclusion
APC specific mutations have potential function as mCRC prognostic biomarkers. There are obvious differences in the gene mutation patterns between the C-terminus and N-terminus APC mutations group, which may have certain guiding significance for the subsequent precise treatment of mCRC.
-
Citations
Citations to this article as recorded by

- In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application
Petar Brlek, Luka Bulić, Nidhi Shah, Parth Shah, Dragan Primorac
International Journal of Molecular Sciences.2025; 26(6): 2568. CrossRef - Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation
Muhammad Tufail, Can-Hua Jiang, Ning Li
Molecular Cancer.2025;[Epub] CrossRef - Investigating the Potential of Natural Agents for Colorectal Cancer Treatment with Molecular Modeling
Eda Arabacı, Nil Sazlı, Deniz Karataş
Karadeniz Fen Bilimleri Dergisi.2025; 15(2): 787. CrossRef - Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies
Neelakanta Sarvashiva Kiran, Chandrashekar Yashaswini, Rahul Maheshwari, Sankha Bhattacharya, Bhupendra G. Prajapati
ACS Pharmacology & Translational Science.2024; 7(4): 967. CrossRef - Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients
Qingqing Qiu
American Journal of Cancer Research.2024; 14(2): 796. CrossRef - Mechanism of APC truncation involved in colorectal cancer tumorigenesis (Review)
Tuya Wang, Jing Fu, Ye Huang, Chun Fu
Oncology Letters.2024;[Epub] CrossRef
-
6,781
View
-
257
Download
-
6
Web of Science
-
6
Crossref
- Gynecologic cancer
-
Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea
-
Kyeongmin Kwak, Seung-sik Hwang
-
Cancer Res Treat. 2024;56(3):898-908. Published online January 15, 2024
-
DOI: https://doi.org/10.4143/crt.2023.981
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
This study aimed to evaluate the effectiveness of the national human papillomavirus (HPV) vaccination program of South Korea among its entire female population, particularly among younger age groups.
Materials and Methods
We first predicted the incidence of cervical cancer over the next 20 years (2021-2040) using the Nordpred package based on Møller’s age-period-cohort model under several scenarios for the national HPV vaccination program. We calculated the potential impact fractions and proportional differences under the current national vaccination programs, and alternative scenarios using the no-vaccination assumption as a reference.
Results
We estimated that the current national vaccination program would prevent 4.13% of cervical cancer cases and reduce the age-standardized incidence rate (ASR) by 8.79% in the overall population by 2036-2040. Under the alternative scenario of implementing the nine-valent vaccine, 5.13% of cervical cancer cases could be prevented and the ASR reduced by 10.93% during the same period. In another scenario, expanding the vaccination age to 9-17 years could prevent 10.19% of cervical cancer cases, with the ASR reduced by 18.57% during the same period. When restricted to ages < 40 years, the prevention effect was remarkably greater. We predict that the current national HPV program will reduce its incidence by more than 30% between 2036 and 2040 in women aged < 40 years.
Conclusion
The effectiveness of the vaccination program in reducing the incidence of cervical cancer was confirmed, with a considerable impact anticipated in younger age groups.
- Lung and Thoracic cancer
-
Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma
-
Mi-Sook Lee, Sungbin An, Ji-Young Song, Minjung Sung, Kyungsoo Jung, Eun Sol Chang, Juyoung Choi, Doo-Yi Oh, Yoon Kyung Jeon, Hobin Yang, Chaithanya Lakshmi, Sehhoon Park, Joungho Han, Se-Hoon Lee, Yoon-La Choi
-
Cancer Res Treat. 2023;55(2):452-467. Published online October 14, 2022
-
DOI: https://doi.org/10.4143/crt.2022.910
-
-
Abstract
PDF
Supplementary Material
PubReader
ePub
- Purpose
NUT carcinoma (NC) is a solid tumor caused by the rearrangement of NUTM1 that usually develops in midline structures, such as the thorax. No standard treatment has been established despite high lethality. Thus, we investigated whether targeting the junction region of NUTM1 fusion breakpoints could serve as a potential treatment option for NC.
Materials and Methods
We designed and evaluated a series of small interfering RNAs (siRNAs) targeting the junction region of BRD4-NUTM1 fusion (B4N), the most common form of NUTM1 fusion. Droplet digital polymerase chain reaction using the blood of patients was also tested to evaluate the treatment responses by the junction sequence of the B4N fusion transcripts.
Results
As expected, the majority of NC fusion types were B4N (12 of 18, 67%). B4N fusion-specific siRNA treatment on NC cells showed specific inhibitory effects on the B4N fusion transcript and fusion protein without affecting the endogenous expression of the parent genes, resulting in decreased relative cell growth and attenuation of tumor size. In addition, the fusion transcript levels in platelet-rich-plasma samples of the NC patients with systemic metastasis showed a negative correlation with therapeutic effect, suggesting its potential as a measure of treatment responsiveness.
Conclusion
This study suggests that tumor-specific sequences could be used to treat patients with fusion genes as part of precision medicine for a rare but deadly disease.
-
Citations
Citations to this article as recorded by

- Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer
Negesse Mekonnen, Hobin Yang, Nirmal Rajasekaran, Kyoung Song, Yoon-La Choi, Young Kee Shin
Translational Oncology.2025; 51: 102204. CrossRef - Precision Targeting of BET Proteins - Navigating Disease Pathways, Inhibitor Insights, and Shaping Therapeutic Frontiers: A Comprehensive Review
Rakesh D. Amrutkar, Mehul V. Amesar, Lokesh B. Chavan, Nilesh S. Baviskar, Vaibhav G. Bhamare
Current Drug Targets.2025; 26(3): 147. CrossRef - NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion
Prerana Jha, Vaishakhi Trivedi, Nandini Menon, Minit Shah, Irene A George, Rohit Mishra, Trupti Pai, Fuzail Ahmad, Venkataramanan Ramachandran, Vanita Noronha, Kumar Prabhash, Prashant Kumar
Cancer Research, Statistics, and Treatment.2024; 7(1): 110. CrossRef
-
6,709
View
-
259
Download
-
2
Web of Science
-
3
Crossref